Thermally controlled intein spliced DNA polymerases and methods of making and using the same

Fusion proteins with intein-controlled DNA polymerases address the challenges of specific amplification and hot-start technologies by using temperature or ion regulation to activate the polymerase, enabling precise and efficient detection of low-copy number nucleic acids.

WO2024233934A1PCT designated stage expired Publication Date: 2024-11-14DUKE UNIV

Patent Information

Application Number
PCT/US2024/028874
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-10
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current DNA polymerase technologies face challenges in controlling polymerase activity to ensure specific amplification of target sequences, leading to mis-priming and mis-extension events, and existing hot-start technologies are limited by defects such as incomplete inhibition, activation issues, and high costs.

Method used

Development of fusion proteins comprising a DNA polymerase with substitution mutations and an intein inserted at a designated position, which inhibits polymerase activity until activated by temperature or divalent ion regulation, allowing for precise and sensitive detection of low-copy number nucleic acids.

Benefits of technology

Enables accurate and sensitive detection of DNA and RNA targets at low copy numbers with high specificity and efficiency, reducing non-specific amplification and improving handling and cost-effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024028874_14112024_PF_FP_ABST
    Figure US2024028874_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to fusion proteins and methods of using the same. Specifically, invention relates to fusion proteins comprising an intein and a DNA polymerase having one or more substitution mutations relative to wildtype, and methods of using the same for DNA synthesis.
Need to check novelty before this filing date? Find Prior Art

Description

Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT THERMALLY CONTROLLED INTEIN SPLICED DNA POLYMERASES AND METHODS OF MAKING AND USING THE SAME FEDERAL FUNDING

[0001] This invention was made with government support under Federal Grant No. NIH 1P01-AI104533-01A1 awarded by the National Institutes of Health. The government has certain rights in the invention. PRIORITY

[0002] This application claims priority to U.S. Provisional Application No. 63 / 465,638, filed May 11, 2023, the entire contents of which are incorporated herein by reference for all purposes. SEQUENCE LISTING The text of the computer readable sequence listing filed herewith, titled “DUKE-43050- 601_SQL”, created May 10, 2024, having a file size of 312,943 bytes, is hereby incorporated by reference in its entirety. TECHNICAL FIELD

[0003] The present disclosure relates to fusion proteins comprising a DNA polymerase variant comprising one or more substitution mutations relative to wildtype, and an intein inserted at a designated position within the DNA polymerase, along with methods of making and using the same. BACKGROUND

[0004] DNA polymerases play a central role in nucleic acid cloning, synthesis, detection, and sequencing. DNA polymerases are used in a variety of molecular diagnostics tools including for detecting infectious agents, cancer, and genetic disease. In combination with reverse transcriptase activity, RNA as well as DNA sequences can be detected at low copy numbers.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT Effective molecular diagnostics relies on the accurate, polymerase-mediated amplification of specific target sequences present in nucleic acids of interest (DNA or RNA) using pairs of oligonucleotide primers that flank the target. Controlling polymerase activity to ensure faithful amplification of a target is challenging, because primers annealed adventitiously at unwanted positions also initialize extension reactions. It is therefore essential that polymerases are active only under conditions at which primers anneal specifically to the intended positions that flank the target.

[0005] The polymerase chain reaction (PCR) relies on iterating cycles of three sequential reactions: target denaturation to form single-stranded templates to which the primers anneal; primer annealing; and polymerase-mediated elongation of the newly annealed primers. Temperature cycling is a widely deployed PCR method to establish optimal conditions for these three reactions: a high-temperature denaturation pulse (∼95°C), followed by an intermediate temperature to establish faithful primer annealing (typically 55–65°C), and a slightly elevated temperature for extension by a thermophilic DNA polymerase (typically 72°C). However, these optimal conditions are established only after transition of the reaction mix from room temperature, prior to which mis-priming and mis-extension events occur readily. To mitigate this problem, ‘hot-start’ polymerase reagents were developed, in which the DNA polymerase is inhibited by addition of a temperature-sensitive inhibitor that is released only at elevated temperatures. However, these hot start technologies are restricted by defects such as incomplete inhibition, incomplete activation, reduced performance, low product yield, time consuming production, high cost, complicated handling, and the like. Accordingly, there remains an urgent need for conditionally activated DNA polymerases that may be used in simple methods of DNA synthesis with high specificity. SUMMARY

[0006] In some aspects, provided herein are fusion proteins comprising a target DNA polymerase comprising one or more substitution mutations relative to the wildtype form of the DNA polymerase, and an intein inserted at a designated position in the target DNA polymerase, wherein insertion of the intein at the designated position inhibits activity of the target DNA polymerase. In some embodiments, the target DNA polymerase is an A family DNA polymeraseAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT or a chimera comprising at least one domain from an A family DNA polymerase, and the target DNA polymerase comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 and having a substitution mutation at position 119 and / or position 509 relative to SEQ ID NO: 1. In some embodiments, the target DNA polymerase comprises a D119A substitution mutation and / or a T509K substitution mutation relative to SEQ ID NO: 1.

[0007] The fusion proteins provided herein are shown to detect target nucleic acids, including target RNA, with high sensitivity. In some embodiments, the fusion proteins provided herein enable detection of target nucleic acids at 1-2 copies of nucleic acid per reaction. In some embodiments, the fusion proteins provided herein enable detection of target RNA even with only 1-2 RNA copies per reaction. In some embodiments, the fusion proteins provided herein enable detection of target nucleic acids at 5-6 copies per reaction. In some embodiments, a substitution mutation at position 119 relative to SEQ ID NO: 1 (e.g. a fusion protein comprising a target A family DNA polymerase having a D119A substitution mutation relative to SEQ ID NO: 1) enables detection of low copy number nucleic acids, RNA targets, and / or RNA-DNA hybrid targets, by preventing digestion of the target nucleic acid by the 5’ ^3’ exonuclease activity of the DNA polymerase. In some embodiments, a substitution mutation at position 509 relative to SEQ ID NO: 1 (e.g. a fusion protein comprising a target A family DNA polymerase having a T509K substitution mutation relative to SEQ ID NO: 1) enables detection of low copy number targets, including low copy number RNA targets, by increasing binding efficiency of the target DNA polymerase. In some embodiments, a fusion provided herein comprises a target A family DNA polymerase having a D119A and a T509K substitution mutation relative to SEQ ID NO: 1.

[0008] In some embodiments, provided herein are compositions comprising a mixture of fusion proteins provided herein. For example, in some embodiments provided herein is a composition comprising a fusion protein comprising a target A family DNA polymerase having a D119A substitution mutation relative to SEQ ID NO: 1 and a fusion protein comprising a target A family DNA polymerase having a T509K substitution mutation relative to SEQ ID NO: 1. In some embodiments provided herein is a composition comprising a fusion protein comprising a target A family DNA polymerase having a D119A substitution mutation and a T509K substitution mutation relative to SEQ ID NO: 1, and a fusion protein comprising a target A family DNA polymerase having a T509K substitution mutation relative to SEQ ID NO: 1. SuchAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT a mixture may be particularly useful for detecting low-copy number targets by methods involving probe hydrolysis.

[0009] In some embodiments, the target DNA polymerase is Taq polymerase or the target DNA polymerase is a chimera comprising at least one domain from Taq polymerase.

[0010] In some embodiments, the intein is inserted within a flexible loop between residues 311-320, residues 381-401, residues 546-597, or residues 782-786 of a Taq polymerase or a corresponding region in a different A family DNA polymerase. In some embodiments, the intein is inserted within a flexible loop between residues 671-686 or residues 734-737 of a Taq polymerase or a corresponding region in a different A family DNA polymerase. In some embodiments, the intein is inserted within a flexible loop between residues 452-545 of a Taq polymerase or a corresponding region in a different A family DNA polymerase. In some embodiments, the intein is inserted within a flexible loop in a thumb domain of the A family DNA polymerase. For example, in some embodiments the intein is inserted within a H1H2 loop of the thumb domain of the A family DNA polymerase.

[0011] For any of the fusion proteins described herein, the wild-type form of the target DNA polymerase may be found in a thermophilic organism. The target DNA polymerase may possess enzymatic activity at temperatures of greater than 50°C. The target DNA polymerase is stable at temperatures of greater than 60°C.

[0012] For the fusion proteins described herein, the intein may be a large intein, a mini- intein, or a split intein. In some embodiments, the intein is selected from PI-PfuI intein, PI-PfuII intein, Tth-HB27 DnaE-1 intein, Neq Pol intein, Tmar Pol intein, Tfu Pol-1 intein, Tfu Pol-2 intein, Pab PolII intein, Pho PolII intein, Tsi PolII intein, Tga PolII intein, Tko PolII intein, Tba PolII intein, Psp-GBD Pol intein, Pho CDC21-1 intein, Pab CDC21-1 intein, Tko CDC21-1 intein, Mja TFIIB intein, Mvu TFIIB intein, Pho RadA intein, Tsi RadA intein, Mja KlbA intein, Pho CDC21-2 intein, Hsp CDC21 intein, Hsp PolII intein, Mth RIR1 intein, Mxe GyrA intein, Tvo VMA intein, Tac VMA intein, Sce VMA intein, Ssp DnaE intein, Npu DnaE intein, Ssp DnaB intein, Npu DnaB intein, Msm DnaB-1 intein, Mtu RecA intein, gp41-1 intein, Tko Pol-2 intein, Cth BIL intein, Cne PRP8 intein, and variants thereof.

[0013] In some embodiments, protein splicing activity of the intein is regulated by one or more factors. In such embodiments, activation of protein splicing results in release of the targetAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT DNA polymerase from the fusion protein. In some embodiments, the released target DNA polymerase possesses increased activity compared to the activity of the target DNA polymerase when present in the fusion protein. For example, the released target DNA polymerase possesses increased DNA polymerase activity and / or increased exonuclease activity compared to the target DNA polymerase when present in the fusion portion. The one or more factors that regulate protein splicing activity of the intein may be temperature, pH, and / or divalent ions. For example, protein splicing activity of the intein may be activated by temperatures of 30°C or greater. In some embodiments, splicing activity of the intein is activated by temperatures of 40°C or greater. In still other embodiments, protein splicing activity of the intein is activated by temperatures of 50°C or greater. In still other embodiments, protein splicing activity of the intein is activated by temperatures of 60°C or greater. In still other embodiments, protein splicing activity of the intein is activated by temperatures of 70°C or greater. In still other embodiments, protein splicing activity of the intein is activated by temperatures of 70°C-80°C.

[0014] In some embodiments, the factor that regulates protein splicing activity of the intein is a divalent ion, wherein the presence of one or more divalent ions inhibits protein splicing activity of the intein. In some embodiments, the protein splicing activity of the intein is activated by addition of a chelator that binds to the divalent ions.

[0015] In some embodiments, wild-type form of the intein is found in a thermophilic organism. The intein may be stable at temperatures of greater than 50°C. In some embodiments, the intein comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3. In some embodiments, the intein comprises the amino acid sequence of SEQ ID NO: 5.

[0016] The fusion proteins described herein may further comprise a purification tag. The purification tag may be inserted within the intein.

[0017] The fusion proteins described herein may be formulated into a composition. In some embodiments, the composition further comprises a nucleic acid template. In some embodiments, the composition further comprises a reaction buffer. Such compositions may be used in methods for amplifying nucleic acid (e.g. amplifying the nucleic acid template). In some embodiments, compositions are in methods of polymerase chain reaction (PCR), reverse-transcription PCR (RT-PCR), isothermal amplification, reverse transcription, or sequencing. For example, compositions described herein may be used in one-step RT-PCR or two-step RT-PCR.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0018] In some aspects, provided herein are methods of amplifying nucleic acid. The methods are performed using a composition comprising a fusion protein as described herein. In some embodiments, methods for amplifying nucleic acid providing a composition comprising a nucleic acid template and a fusion protein comprising a target DNA polymerase and an intein inserted at a designated position in the target DNA polymerase. Insertion of the intein at the designated position inhibits activity of the target DNA polymerase. The methods further comprise changing one or more factors to induce release of the target DNA polymerase from the fusion protein. The released target DNA polymerase possesses increased activity compared to the target DNA polymerase containing the inserted intein. The methods further comprise amplifying the nucleic acid template in the composition. In some embodiments, the protein splicing activity of the intein is regulated by the one or more factors. Modification of the one or more factors thereby induces activation of protein splicing, resulting in release of the target DNA polymerase from the fusion protein. For example, modulation of the one or more factors may comprise changing the temperature (e.g. increasing the temperature to induce splicing activity of the intein) or adding a chelating agent to bind divalent ions in the sample. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIGs. 1A-1I show design of intein-controlled DNA polymerases. DNA polymerases from different families (Taq (FIG. 1A), PDB 1TAQ (FIG. 1B), 3KTQ (FIG. 1C); Pfu (FIG. 1D) PDB 4AIL (FIG. 1E) have conserved (sub)domains palm, fingers, and thumb. Taq has 5’ ^ 3’ and vestigial 3’ ^ 5’ exonuclease domains. Pfu has a functional 3’ ^ 5’ exonucleaseThe fused is shown in red (1DQ3). FIG. 1A shows DNA polymerase. Theintein is inserted into a thumb domain surface loop between residues 505 and 506. FIG. 1B shows the InTaq thumb domain before (left) and after (right) splicing (H1 and H2 helices are indicated). The loop conformations were remodeled to remove van der Waals clashes between intein and the Taq domains. Insertion point: −1, last residue in the N-extein corresponds to residue 505; +1, first residue in the C-extein corresponds to residue 506. Mutants K505G and E507G complete the GGTG (SEQ ID NO: 6) insertion point tetrapeptide. FIG. 1C shows the structurally conserved thumb domain loops in A family DNA polymerases (dashed circle; red line, InTaq intein insertion point) are diverse in sequence (Taq, 3KTQ; human Polθ, 4X0P; T7Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT DNA polymerase, 1SL0). FIG. 1D shows InPfu DNA polymerase. The intein is inserted in a thumb domain surface loop between residue 707 and 708. FIG. 1E shows the model of InPfu thumb domain before (left) and after (right) splicing (U and V helices are indicated). The loop conformations were remodeled by inspection to remove van der Waals clashes between intein and the Pfu domains. Insertion point: −1, last residue in the N-extein corresponds to residue 707; +1, first residue in the C-extein corresponds to residue 708. D708T and a two-glycine insertion (green −2 , −3 ) complete the GGTG (SEQ ID NO: 6) insertion point; P710K increases loop flexibility. FIG. 1F shows structurally conserved thumb domain loops (dashed circle; red line, InPfu intein insertion point) in B family DNA polymerases (Pfu, 4AIL; human Polδ, 6TNY; E. coli PolII, 3K5N). FIG. 1G shows the Mini intein. The endonuclease domain of wild-type PI- PfuI intein is replaced by a 6xHis affinity tag for purification. FIG. 1H shows InTaq mutations for enhancing RNA detection sensitivity. The D119A mutation is designed to reduce 5’ ^ 3’ exonuclease activity that degrades target RNA using endogenous RNase H activity.T509K mutation is intended to enhance the DNA substrate binding affinity. FIG. 1I shows the KlenTaq polymerase lacks the 5’ ^ 3’ exonuclease domain.

[0020] FIGs. 2A-2F show protein splicing is dependent on temperature and can be controlled with divalent cations. FIG. 2A and FIG. 2 B show time course of the splicing reaction at 80°C. The splicing products were analyzed by Coomassie Blue stained SDS-PAGE (black arrow, full length InTaq or InPfu; open arrow, mature, spliced polymerase; asterisk, uncharacterized cleavage byproduct). FIG. 2C shows temperature dependence of InTaq splicing. The time course of the mature spliced polymerase fraction was measured at different incubation temperatures (band intensities were quantified on images of Coomassie Blue stained gels using ImageJ); the mature protein band fractions were normalized by the intensities of all observable bands). Fig. 2D shows the effect of divalent cations on InTaq splicing. The relative splicing activities of InTaq were measured in the presence of 1 mM cations (the splicing rate of InTaq in the absence of added cations is defined as 100%). FIG. 2E shows reversible inhibition of splicing by Zn2+. The splicing was fully inhibited by 1 mM Zn2+, and rescued by addition of the chelator EGTA at 5 mM. Error bars were generated from triplicate repeats. FIG. 2F shows Zn2+-inhibited InTaq remains inactive even after a 1-h 75°C heat pulse, which activates antibody- and aptamer-Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT inhibited Taq. DNA polymerase activity was measured using a self-priming extension assay visualized by urea-PAGE (black arrow, substrate; open arrow, extended product).

[0021] FIGs. 3A-3D show protein splicing controls DNA polymerase activity. FIG. 3A shows DNA polymerase activities of intact and spliced InTaq or InPfu. The polymerase activity was measured using elongation of a hairpin DNA substrate (top panel). The reaction products were analyzed by ethidium bromide stained urea-PAGE (bottom panel; black arrow, DNA substrate; open arrow, the elongated product). WtTaq and spliced InTaq showed comparable polymerase activity at 21°C or 70°C, whereas a 100-fold higher concentration of unspliced InTaq did not show detectable activity at 21°C. Similarly, the unspliced InPfu was inactive, whereas its spliced form is active. FIG. 3B shows thermostability of WtTaq and InTaq−. Melting temperatures were determined using thermal melts with SYPRO Orange. Both proteins exhibit dual transitions, corresponding to independent (un)folding of the polymerase (Pol) and 5′→3′ exonuclease (Exo) domains. FIG. 3C shows protein splicing controls DNA substrate binding to InKlenTaq. Binding was measured by the dependence on protein concentration of fluorescence polarization (ΔmP) for unspliced (orange; no binding) and spliced (blue; binding) proteins (data points are indicated by circles and squares; error bars were generated by triplicate repeats). FIG. 3D shows intein controls exonuclease activity of InPfu. A DNA hairpin was used as the 3′→5′ exonuclease substrate. The reaction products were analyzed by ethidium bromide stained 10% urea-PAGE (black arrow, full-length substrate; open arrow, cleaved products). Polymerases were incubated with the DNA substrate at 50°C for 1 h. Without splicing, no detectable DNA degradation is observed, while the spliced InPfu shows the comparable exonuclease activity as wild-type Pfu polymerase (WtPfu).

[0022] FIGS. 4A-4C show InTaq and InPfu are effective reagents for accurate, hot-start PCR. FIG. 4A shows a comparison of hot-start activation on InTaq and commercially available hot-start Taq polymerases using a self-priming elongation reaction analyzed with ethidium bromide-stained urea-PAGE (black arrow, primer; open arrow, elongated product). Top, no heat activation. Bottom, 30 min heat treatment at 80°C, followed by a polymerization reaction for 5 min at 70°C. InTaq and Antibody-Taq both require heat activation. Aptamer-Taq is only partially inactivated at 30°C. Following the heat pulse, all polymerases are fully active. A 30-min, instead of the 10-min typical activation time (see C) was used to ensure that the Antibody inhibitor in theAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT control was inactivated because it is usually denatured at temperatures in excess of 80°C that decrease intein excision rates. FIG. 4B shows PCR amplification by InTaq (top) and InPfu (bottom) of various plasmid DNA substrates with target lengths from 0.3kb to 6.1kb, visualized on a 1% agarose gel. FIG. 4C shows detection of serially diluted SARS-CoV-2 N1 template DNA by qPCR, using the N1 sequence as the amplification target. Top, InTaq; bottom, WtTaq. Left panels: dependence of EvaGreen fluorescence on amplification cycle for different template copy numbers (high copy numbers are amplified at low cycle numbers); right panels, thermal melts of PCR reaction products; legend relates approximate copy number (NTC, no template control) to the number of cycles at which the fluorescence reliably exceeds background, Cq. InTaq was activated by initial 10 min incubation at 70°C prior to amplification.

[0023] FIGs. 5A-5E show high-sensitivity RNA detection with InTaq. FIG. 5A shows the D119A mutant in InTaqE−reduces RNA substrate degradation. The presence of SARS-CoV-2 genomic RNA was detected with a New England Biolabs kit using the standard CDC N1 primer / probe set. The RNA was incubated with InTaq in the presence and absence of Mg2+, and two additional primers that could evoke RNase H activity. A large Cq value (pink) was indicative of RNA degradation which occurred only in the presence of InTaq, primers, and Mg2+ion at 60°C. Under identical conditions, InTaqE−(D119A) does not degrade RNA (yellow). FIG. 5B shows the T509K mutation in InTaqB+improves detection sensitivity of qPCR of a 72- nucleotide N1 fragment (see C). FIG. 5C shows optimization of the InTaqE−B+:InTaqB+ratio for RT-qPCR using probe hydrolysis. The SARS-CoV-2 genomic RNA was detected using the standard CDC N1 primer set using a doubly labeled fluorescent probe. Each enzyme ratio was evaluated using by Cq value (top panel), and total, end-point fluorescence signal (bottom panel). In the absence of InTaqB+(10:0), no signal was observed because the probe did not hydrolyze. In the absence of InTaqE−B+(0:10), the RT-qPCR was ineffective, because RNase H activity overwhelmed the reaction. The 10:4 ratio provided an effective blend of requisite activities. FIG. 5D shows SARS-CoV-2 RNA was detected accurately and sensitively by InTaqE−B+using the CDC N1 primer and hydrolysis probe set. Blue line, 10:4 InTaqE−B+: InTaqB+blend, each reaction has three or more repeats; grey line, InTaqB+only. Inset: fraction of RT-qPCR independent trials that successfully exhibited a fluorescent signal. Given s successful outcomes in N trials, Laplace's rule of succession states that the probability of success in N+ 1 trials isAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT given byminimum 20 trials recommended by the FDA, the certainty of the method at 5 copies or above therefore is (20+1) / (20+2) = 0.95. FIG. 5E shows accurate and sensitive detection of SIV gag RNA using the 10:4 InTaqE−B+: InTaqB+blend (see Table 1 for primer and probe sequences).

[0024] FIG. 6 shows EGTA reverses RT-qPCR inhibition by Zn2+. The template (6000 copies), primers, and reaction conditions are the same as in Figure 5D of the main text. The reactions were supplied with or without 5 mM EGTA and additional 1 mM Zn2+ as indicated in the figure.

[0025] FIGs. 7A-7C show detection of serially diluted SARS-CoV-2 template DNA by qPCR, using InTaq, Aptamer-Taq or Antibody-Taq. Each serial dilution is distinguished by color (see legend) and was measured in triplicate. The template, primers, and reaction conditions are the same as in Figure 4C of the main text. (FIG. 7A) InTaq; (FIG. 7B) Aptamer-Taq; (FIG. 7C) Antibody-Taq. Left panels: dependence of EvaGreen fluorescence on amplification cycle for different template copy S4 numbers (high copy numbers are amplified at low cycle numbers); right panels, thermal melts of PCR reaction products. InTaq was activated by initial 10 min incubation at 70 °C prior to amplification. Aptamer-Taq or Antibody-Taq was activated by initial 94 °C for 5 min.

[0026] FIG. 8 shows SARS-CoV-2 N gene DNA (DNA standard) was detected accurately and sensitively by 10:4 InTaqE-B + : InTaqB+ blend in probe based qPCR reactions. The primers and reaction conditions are the same as in Figure 5D of the main text. The reactions were amplified by qPCR: 70 °C for 10 min and 94 °C for 1 min; followed by 45 thermal cycles of 94 °C for 1 sec and 60 °C for 30 sec. Each reaction has three or more repeats (inset, fraction of qPCR repeats that exhibited a fluorescent signal). The Limit of detection is 5 copies per reaction DETAILED DESCRIPTION

[0027] In some aspects, provided herein are fusion proteins comprising a target DNA polymerase comprising one or more substitution mutations relative to wildtype and an intein, and methods of using the same. In some embodiments, the one or more substitution mutations reduces 5’ ^ 3’ exonuclease activity that otherwise degrades target RNA. In some embodiments, the one or more substitution mutations enhance the DNA substrate binding affinity.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0028] The intein may be inserted at a suitable position within the DNA polymerase to suppress activity of the DNA polymerase while the intein is present. The activity (e.g. splicing) of the intein may be regulated by one or more external factors, thereby producing an intein- controlled DNA polymerase that is active only when the intein is excised from the fusion protein and the DNA polymerase is freed.

[0029] The engineered polymerases presented herein provide a straightforward thermal activation step for highly effective, single-reagent ‘hot-start’ control that enables accurate detection of DNA or RNA targets at low copy numbers. Hot-start polymerases are useful not only for the PCR schemes that rely on temperature cycling such as used herein, but also for schemes that amplify isothermally at elevated temperatures, such as loop-mediated isothermal amplification.

[0030] An intein (intervening protein) is a protein that can, under the appropriate conditions, autocatalytically excise itself from a protein precursor through the cleavage of two peptide bonds, and concomitantly ligate the flanking protein fragments through the formation of a new peptide bond to produce a mature host protein (referred to as an extein, or external protein). This intein catalyzed process is called protein splicing. This protein splicing process requires no external energy source. Although the diverse sequences of inteins lead to different precise splicing processes, they all share similar structural folding and a similar splicing mechanism. In a basic sense, the splicing process starts with the peptide bond cleavage between intein and -1 residue, which is the extein residue linking to the N-terminus of the intein (the residue linking to the N-terminus of -1 residue is -2 residue, and so on). A (thio)ester bond is subsequently formed between -1 residue and the side chain of +1 residue, which is the extein residue linking to the C- terminus of the intein (the residue linking to the C-terminus of +1 residue is +2 residue, and so on). The +1 residue is cysteine, serine, or threonine in all known inteins. Afterward, the peptide bond between intein and +1 residue is cleaved, leading to the releasing of the intein. Finally, the (thio)ester bond between -1 residue and the side chain of +1 residue breaks, and the peptide bond between -1 and +1 residues forms, resulting in the mature extein. During the splicing process, inteins can also generate side products such as the free N- or C-terminal exteins (the extein fragment linked to the N- or C-terminal of intein) by N- or C-terminal cleavage, respectively. Intein splicing can be dependent on temperature, ionic strength, divalent cations, pH, andAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT reducing potential. Herein, it is shown that intein splicing provides effective in vitro control of DNA polymerases, and it is demonstrated how these temperature-dependent splicing reactions can be used for accurate and sensitive molecular diagnostics.

[0031] For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the disclosure is thereby intended, such alteration and further modifications of the disclosure as illustrated herein, being contemplated as would normally occur to one skilled in the art to which the disclosure relates. 1. Definitions

[0032] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0033] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0034] The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context.

[0035] As used herein, the term “about” is used to provide flexibility to a numerical range endpoint by providing that a given value may be “slightly above” or “slightly below” the endpoint without affecting the desired result. In some embodiments, “about” may refer toAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount.

[0036] As used herein, the terms “comprise”, “include”, and linguistic variations thereof denote the presence of recited feature(s), element(s), method step(s), etc. without the exclusion of the presence of additional feature(s), element(s), method step(s), etc.

[0037] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise-indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if a concentration range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. These are only examples of what is specifically intended, and all possible combinations of numerical values between and including the lowest value and the highest value enumerated are to be considered to be expressly stated in this disclosure.

[0038] The term “amino acid” refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers, unless otherwise indicated, if their structures allow such stereoisomeric forms.

[0039] Natural amino acids include alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), Lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y) and valine (Val or V).

[0040] Unnatural amino acids include, but are not limited to, azetidinecarboxylic acid, 2- aminoadipic acid, 3-aminoadipic acid, beta-alanine, naphthylalanine (“naph”), aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2- aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine (“tBuG”), 2,4-diaminoisobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3- diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline (“hPro” or “homoP”), hydroxylysine, allo-hydroxylysine, 3-hydroxyproline (“3Hyp”), 4-hydroxyproline (“4Hyp”), isodesmosine, allo-isoleucine, N-methylalanine (“MeAla” or “Nime”), N-alkylglycine (“NAG”)Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT including N-methylglycine, N-methylisoleucine, N-alkylpentylglycine (“NAPG”) including N- methylpentylglycine. N-methylvaline, naphthylalanine, norvaline (“Norval”), norleucine (“Norleu”), octylglycine (“OctG”), ornithine (“Orn”), pentylglycine (“pG” or “PGly”), pipecolic acid, thioproline (“ThioP” or “tPro”), homoLysine (“hLys”), and homoArginine (“hArg”).

[0041] The term “amino acid analog” refers to a natural or unnatural amino acid where one or more of the C-terminal carboxyl group, the N-terminal amino group and side-chain bioactive group has been chemically blocked, reversibly or irreversibly, or otherwise modified to another bioactive group. For example, aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is an amino acid analog of alanine. Other amino acid analogs include methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S- (carboxymethyl)-cysteine sulfone.

[0042] As used herein, a “conservative” amino acid substitution refers to the substitution of an amino acid in a peptide or polypeptide with another amino acid having similar chemical properties, such as size or charge. For purposes of the present disclosure, each of the following eight groups contains amino acids that are conservative substitutions for one another:

[0043] 1) Alanine (A) and Glycine (G);

[0044] 2) Aspartic acid (D) and Glutamic acid (E);

[0045] 3) Asparagine (N) and Glutamine (Q);

[0046] 4) Arginine (R) and Lysine (K);

[0047] 5) Isoleucine (I), Leucine (L), Methionine (M), and Valine (V);

[0048] 6) Phenylalanine (F), Tyrosine (Y), and Tryptophan (W);

[0049] 7) Serine (S) and Threonine (T); and

[0050] 8) Cysteine (C) and Methionine (M).

[0051] Naturally occurring residues may be divided into classes based on common side chain properties, for example: polar positive (or basic) (histidine (H), lysine (K), and arginine (R)); polar negative (or acidic) (aspartic acid (D), glutamic acid (E)); polar neutral (serine (S), threonine (T), asparagine (N), glutamine (Q)); non-polar aliphatic (alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M)); non-polar aromatic (phenylalanine (F), tyrosine (Y), tryptophan (W)); proline and glycine; and cysteine. As used herein, a “semi-conservative”Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT amino acid substitution refers to the substitution of an amino acid in a peptide or polypeptide with another amino acid within the same class.

[0052] In some embodiments, unless otherwise specified, a conservative or semi- conservative amino acid substitution may also encompass non-naturally occurring amino acid residues that have similar chemical properties to the natural residue. These non-natural residues are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include, but are not limited to, peptidomimetics and other reversed or inverted forms of amino acid moieties. Embodiments herein may, in some embodiments, be limited to natural amino acids, non-natural amino acids, and / or amino acid analogs.

[0053] Non-conservative substitutions may involve the exchange of a member of one class for a member from another class.

[0054] The term “consensus sequence” as used herein refers to the -3, -2, -1, +1, +2, and +3 extein residues. The desired consensus sequence may exist naturally or may be engineered (e.g. by one or more mutations in the DNA polymerase). These residues support the function of the intein (e.g. support intein splicing).

[0055] The term “intein” as used herein refers to a protein that can autocatalytically excise itself from a protein precursor and concomitantly ligate the flanking protein fragments to produce a mature protein. The term “extein” as used herein refers to the mature protein produced as a result of such a process. The autocatalytic excision process performed by the intein to produce the mature protein is referred to herein as “splicing” or “protein splicing”.

[0056] “Identical” or “identity,” as used herein in the context of two or more polypeptide, amino acid, or polynucleotide sequences, can mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage can be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified regionAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT of comparison includes only a single sequence, the residues of the single sequence are included in the denominator but not the numerator of the calculation.

[0057] “Variant” is used herein to describe a protein (e.g. a polymerase, an intein) that differs from a reference protein in amino acid sequence by the insertion, deletion, or substitution of amino acids, but retains at least one biological activity of the reference protein. Representative examples of “biological activity” include the ability to perform a typical enzymatic function associated with that protein (e.g. for polymerases, to retain polymerase and / or exonuclease activity and for inteins, to retain protein splicing ability). For example, a variant of a polymerase may differ in amino acid sequence from the wild-type polymerase, but still retains at least one biological activity (e.g. functional polymerase activity, functional exonuclease activity) compared to the wild-type. As another example, a variant of an intein may differ in amino acid sequence from the wild-type intein, but still retain at least one biological activity (e.g. functional protein splicing) compared to the wild-type. A “variant” may also be referred to as a “mutant” or an “engineered” version herein. A “variant” of a full-length intein may be a mini-intention derived therefrom, such as by removing the endonuclease domain from the full-length intein. 2. Fusion Proteins

[0058] In some aspects, provided herein are engineered fusion proteins comprising a target DNA polymerase comprising one or more substitution mutations relative to the wildtype DNA polymerase, and an intein inserted at a designated position within the target DNA polymerase. Currently, DNA polymerases are classified into A, B, C, D, X, Y, and RT (reverse transcriptase) families according to sequence similarity. A, B, C, D, X, and Y family DNA polymerases mainly utilize DNA as the template for DNA synthesis, while RT family DNA polymerases mainly utilize RNA as the template for DNA synthesis (reverse transcription). All DNA polymerases synthesize DNA by transferring deoxyribonucleotides from dNTPs onto the 3’-OH group of the newly synthesized strand, catalyzing the 5’ to 3’ polymerase activity. In some embodiments, the fusion protein comprises an A family DNA polymerase or a chimera comprising at least one domain from an A family polymerase, wherein the polymerase comprises one or more substitution mutations relative to the wildtype A family DNA polymerase. For example, in some embodiments the fusion protein comprises a Taq DNA polymerase or a chimera comprising atAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT least one domain from Taq DNA polymerase, wherein the polymerase comprises one or more substitution mutations relative to wildtype Taq DNA polymerase.

[0059] In some embodiments, target DNA polymerase is an A family DNA polymerase or a chimera comprising at least one domain from an A family DNA polymerase, wherein the A family DNA polymerase or domain therefrom comprises one or more substitution mutations relative to the wildtype form of the polymerase. Suitable A family DNA polymerases, including for example, Taq (UniProt ID: P19821, Thermus aquaticus DNA polymerase I), Tth (UniProt ID: P52028, Thermus thermophilus HB8 DNA polymerase I), Tfl (UniProt ID: P30313, the DNA polymerase isolated from Thermus flavus), Tfi (UniProt ID: O52225, Thermus filiformis DNA polymerase I), Tbr (UniProt ID: A0A1J0LQA5, Thermus brockianus DNA polymerase I, commercial name: DyNAzyme), Tca (UniProt ID: P80194, Thermus caldophilus DNA polymerase I), Tma (UniProt ID: Q9X1V4, Thermotoga maritima DNA polymerase I, commercial name: UITma DNA polymerase), Tne (UniProt ID: B9K7T2, Thermotoga neapolitana DNA polymerase I), Bst (UniProt ID: Q45458, Geobacillus stearothermophilus (previously Bacillus stearothermophilus) DNA polymerase I), Bsm (UniProt ID: Q08IE4, Bacillus smithii DNA polymerase I), Bsu (UniProt ID: O34996, Bacillus subtilis DNA polymerase I), Escherichia coli DNA polymerase I (UniProt ID: P00582), Bacteriophage T7 DNA polymerase (UniProt ID: P00581), 3173 Pol (GenBank: ADL99605.1, a viral DNA polymerase homologous to Thermocrinis albus Pol I (Genbank: ADC89878.1) and commercialized by Lucigen with names OmniAmp polymerase or PyroPhage 3173 DNA polymerase), and variants of any of the above. For example, variants of any of the above may comprise suitable amino acid mutations (e.g. substitutions, insertions, deletions, etc.) to improve one or more characteristics of the polymerase. For example, variants of the above may be employed to improve reaction fidelity, enhance DNA binding affinity, enhance thermal stability, or other desired characteristics of the DNA polymerase.

[0060] In some embodiments, the target DNA polymerase comprises an amino acid sequence having 80% or more sequence identity with an A family target DNA polymerase, such as an A family target DNA polymerase listed above, and has one or more substitution mutations relative to the wildtype form of the target DNA polymerase. For example, the target DNA polymerase may comprise an amino acid sequence having at least 80%, at least 81%, at least 82%, at leastAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with an A family target DNA polymerase and have one or more substitution mutations relative to the wildtype A family target DNA polymerase.

[0061] In some embodiments, the target DNA polymerase is an A family DNA polymerase or a chimera comprising at least one domain from an A family DNA polymerase, wherein the target DNA polymerase comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 and has a substitution mutation at position 119 and / or position 509 relative to SEQ ID NO: 1. SEQ ID NO: 1 corresponds to the wildtype Taq polymerase sequence, and is set forth below:

[0062] MRGMLPLFEPKGRVLLVDGHHLAYRTFHALKGLTTSRGEPVQAVYGFAKSL LKALKEDGDAVIVVFDAKAPSFRHEAYGGYKAGRAPTPEDFPRQLALIKELVDLLGLAR LEVPGYEADDVLASLAKKAEKEGYEVRILTADKDLYQLLSDRIHVLHPEGYLITPAWLW EKYGLRPDQWADYRALTGDESDNLPGVKGIGEKTARKLLEEWGSLEALLKNLDRLKPA IREKILAHMDDLKLSWDLAKVRTDLPLEVDFAKRREPDRERLRAFLERLEFGSLLHEFGL LESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDL KEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAG ERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGVRLDVAYLRALSL EVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEA LREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQ NIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLIRVFQEGRDIHTETA SWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQSFPK VRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAAD LMKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEGVYPLAVP LEVEVGIGEDWLSAKE (SEQ ID NO: 1).

[0063] In some embodiments, the target DNA polymerase (e.g. the A family DNA polymerase) has at least 80% sequence identity (e.g. at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identity) to SEQ ID NO: 1, and comprises a D119A substitution mutationAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT and / or a T509K substitution mutation relative to SEQ ID NO: 1. In some embodiments, the target DNA polymerase (e.g. the A family DNA polymerase) has at least 80% sequence identity (e.g. at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identity) to SEQ ID NO: 1, and comprises a D119A substitution relative to SEQ ID NO: 1. In some embodiments, the target DNA polymerase (e.g. the A family DNA polymerase) has at least 80% sequence identity (e.g. at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identity) to SEQ ID NO: 1, and comprises a T509K substitution mutation relative to SEQ ID NO: 1. In some embodiments, the target DNA polymerase (e.g. the A family DNA polymerase) has at least 80% sequence identity (e.g. at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identity) to SEQ ID NO: 1, and comprises a D119A substitution mutation and a T509K substitution mutation relative to SEQ ID NO: 1.

[0064] In some embodiments, the target DNA polymerase is Taq polymerase or a variant thereof. In some embodiments, the target DNA polymerase is a Taq polymerase having an amino acid sequence having at least 80% sequence identity (e.g. at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) with SEQ ID NO: 1 and having a D119A substitution mutation and / or a T509K substitution mutation relative to SEQ ID NO: 1. In some embodiments, the target DNA polymerase is a Taq DNA polymerase having at least 90% (e.g. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identity) to SEQ ID NO: 1 and having a D119A substitution mutation and / or a T509K substitution mutation relative to SEQ ID NO: 1.

[0065] Despite the sequence diversity among polymerase families, activity centers of all DNA polymerases contain palm, thumb, and finger domains. Conserved residues in the palm domain coordinate divalent metal ions to catalyze the polymerase reaction. The finger domain mainly binds the incoming dNTP. The thumb domain facilitates proper interaction between the DNA duplex and the DNA polymerase. In addition to the polymerase activity, many DNAAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT polymerases have other activities, such as nuclease activity and strand displacement activity, which are generally catalyzed by additional regions or domains. In some embodiments, the DNA polymerase comprises a palm domain, a thumb domain, and a finger domain. In some embodiments, the DNA polymerase comprises a palm domain, a thumb domain, a finger domain, and an exonuclease domain. In some embodiments, the intein is inserted within the thumb domain of the target DNA polymerase.

[0066] In some embodiments, the wild-type form of the target DNA polymerase is found in a thermophilic organism. The target DNA polymerase may possess enzymatic activity at temperatures usually employed for isothermal amplification, reverse transcription, polymerase chain reaction, etc. In some embodiments, the target DNA polymerase demonstrates enzymatic (e.g. polymerase) activity at temperatures of greater than 50℃, so long as the DNA polymerase is not bound to the intein. The temperature of 50℃ is not a lower limit, the target DNA polymerase may also possess enzymatic activity at temperatures of lower than 50℃. For example, the DNA polymerase may possess enzymatic activity at temperatures of 20℃, 30℃, 40℃, 50℃, and higher than 50℃. In some embodiments, the target DNA polymerase is stable at temperatures of greater than 60℃.

[0067] In some embodiments, the target DNA polymerase comprises one or more mutations to support intein splicing. For example, one or more residues may be mutated to a glycine to support intein splicing. Selection of which particular residues may be mutated to glycine may depend on the designated position for intein insertion. For example, one or residues proximal to (e.g. within 5 amino acids) the intein insertion site (e.g. proximal to the N-terminal amino acid of the inserted intein and / or proximal to the C-terminal amino acid of the inserted intein) may be mutated to a glycine. For example, to support intein splicing it may be desirable that the -5, -4, - 3, -2, -1, +1, +2, +3, +4, and / or +5 residue is a glycine and suitable mutations may be made in order to accomplish this.

[0068] In some embodiments, the amino acid immediately proximal to the N-terminal amino acid of the inserted intein (e.g. the -1 residue) may be a glycine. This may occur naturally (e.g. the intein insertion site may be selected such that the -1 residue is a glycine) or the residue may be mutated to a glycine. In some embodiments, the -1 residue and the -2 residue may be a glycine (e.g. naturally or by mutation). In some embodiments, the -1 residue, the -2 residue, andAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT the -3 residue may be a glycine (e.g. naturally or by mutation). In some embodiments, the +2 and / or +3 residue is mutated to be a glycine to support intein splicing.

[0069] In some embodiments, the +1 residue (e.g. the residue immediately proximal to the C- terminal amino acid of the intein) is a cysteine, a serine, or threonine. This may occur naturally. For example, the intein insertion site may be selected such that the +1 residue is known to be a cysteine, a serine, or a threonine. In other embodiments, the +1 residue may be mutated to be a cysteine, a serine, or a threonine. In some embodiments, an intein naturally containing a +1 residue that is already a cysteine, a serine, or a threonine may be mutated that the +1 residue is changed from the existing cysteine, serine, or threonine to a different option of these three amino acids. For example, a +1 cysteine could be changed to a +1 serine or a +1 threonine. As another example, a +1 serine could be changed to a +1 cysteine or a +1 threonine.

[0070] In some embodiments, the target DNA polymerase is possesses reverse transcriptase activity. For example, the target DNA polymerase an A family DNA polymerase that can use RNA as a template. Some A family DNA polymerases can use RNA as the template, therefore they have been developed for reverse transcription, including Taq polymerase, Tth polymerase, Tfl polymerase, 3173 Pol, Bst polymerase, Bsm polymerase, Bsu polymease and Escherichia coli DNA polymerase I. In some embodiments, the DNA polymerase may be modified (e.g. by one or more mutations) such that it possesses reverse transcriptase activity or to improve innate reverse transcriptase ability. For example, Taq may be modified to improve its reverse transcription activity.

[0071] In some embodiments, the target DNA polymerase is a chimera comprising at least one domain from an A family DNA polymerase. The chimera may comprise at least one domain from one DNA polymerase, and at least one domain from a different DNA polymerase. In some embodiments, the chimera comprises at least one domain from an A family DNA polymerase and at least one domain from a different A family DNA polymerase. Suitable A family DNA polymerases are described above, including Taq polymerase, Tth polymerase, Tfl polymerase, Tfi polymerase, Tbr polymerase, Tca polymerase, Tma polymerase, Tne polymerase, Bst polymerase, Bsm polymerase, Bsu polymerase, Escherichia coli DNA polymerase I, Bacteriophage T7 DNA polymerase, 3173 Pol, and variants thereof.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0072] The fusion protein further comprises an intein inserted at a designated position in the target DNA polymerase. In some embodiments, insertion of the intein at the designated position inhibits activity of the target DNA polymerase. For example, insertion of the intein at the designated position in the target DNA polymerase may inhibit polymerase activity of the target DNA polymerase. As another example, insertion of the intein at the designated position in the target DNA polymerase may inhibit exonuclease activity of the target DNA polymerase. In some embodiments, insertion of the intein at the designated position in the target DNA polymerase may inhibit polymerase and exonuclease activity of the target DNA polymerase.

[0073] In some embodiments, the intein may be inserted at a designated position in the target DNA polymerase such that binding of a substrate (e.g. DNA) to the active site of the target DNA polymerase is inhibited. For example, the intein may be inserted at a suitable position within the target DNA polymerase to 1) physically block the DNA polymerase active site; and / or 2) compromise the DNA binding ability of the DNA polymerase; and / or 3) disrupt the function of DNA polymerase allosterically.

[0074] The intein may be inserted in any suitable location within the target DNA polymerase to. In general, a suitable insertion location within the target DNA polymerase should inhibit activity (e.g. polymerase activity, exonuclease activity, reverse transcriptase activity) of the target DNA polymerase activity when the intein is fused, support the intein protein splicing reaction, and result in a functional DNA polymerase after the intein is spliced.

[0075] To support the intein protein splicing reaction, the insert position should not affect the structure and function of the inserted intein. Moreover, the insert position should be able to provide the extein -3 to -1 and +1 to +3 residues (also referred to herein as the “consensus sequence”) that support intein splicing. If the extein -3 to -1 and +1 to +3 residues do not naturally exist in the DNA polymerase, such sequences may be inserted artificially into the DNA polymerase.

[0076] To result in a functional DNA polymerase after the intein is spliced, the insertion position should enable the release of the intein from the DNA polymerase. Moreover, the extein - 3 to -1 and +1 to +3 residues remaining after protein splicing should have limited or no effect on the activity or function of the released DNA polymerase. Similarly, if the extein -3 to -1 and +1Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT to +3 residues are mutated to support protein splicing, the extein mutations should have limited or no effect on the activity or function of the released DNA polymerase.

[0077] In some embodiments, the intein is flanked by an N-terminal extein and a C-terminal extein of the target DNA polymerase. In some embodiments, the last two amino acids in the N- terminal extein are GG or are mutated to be GG, and the first two amino acids in the C-terminal extein are TG or mutated to be TG. Accordingly, upon excision of the intein the resulting extein comprises the sequence GGTG (SEQ ID NO: 6). This sequence is referred to herein as a GGTG (SEQ ID NO: 6) insertion point or splice point.

[0078] In some embodiments, a short linker sequence or multiple short linker sequences may be added to enable the proper insertion of the intein. Such short linker(s) also should have limited or no effect on the activity or function of the DNA polymerase.

[0079] Exemplary inteins, DNA polymerases, and insertion sites for the intein within the DNA polymerase are described in WO2022046162A1, the entire contents of which are incorporated herein by reference for all purposes. In some embodiments, the intein is inserted within a flexible loop of the target DNA polymerase. Since such loops are structurally flexible, they demonstrate more plasticity to support the intein for the protein splicing reaction. In addition, the flexibility of loops also decreases interference from other parts of the DNA polymerase. In some embodiments, the flexible loop is within the thumb domain, a finger domain, the palm domain, or the exonuclease domain of the target DNA polymerase. In particular embodiments, the intein may be inserted within a flexible loop proximal to the active site. In some embodiments, the intein may be inserted such that the intein is between 10 to 50 Å of the active site of the target DNA polymerase. For example, the insertion position may be about 10 Å, about 15 Å, about 20 Å, about 25 Å, about 30 Å, about 35 Å, about 40 Å, about 45 Å, or about 50 Å from the active site.

[0080] In some embodiments, the target DNA polymerase is an A family DNA polymerase or a chimera comprising at least one domain from an A family DNA polymerase. In some embodiments, the target DNA polymerase is Taq polymerase or a variant thereof. In some embodiments, the intein is inserted within a flexible loop between residues 311-320, residues 381-401, residues 546-597, or residues 782-786 of the Taq polymerase. These residues are found within the palm domain. In other embodiments, the intein is inserted within a flexibleAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT loop between residues 671-686 or residues 734-737 of the Taq polymerase. These residues are found within a finger domain. In still other embodiments, the intein is inserted within a flexible loop between residues 452-545 of the Taq polymerase. These residues are found within the thumb domain. Although these residue numbers are specific for Taq polymerase, these residues may be used to determine the corresponding residues for suitable intein insertion locations in other A family DNA polymerases. Accordingly, the intein may be inserted at a flexible loop within the above-described residues of Taq polymerase or in a corresponding flexible loop of a different A family DNA polymerase. Sequence alignment may be used to determine appropriate corresponding locations. For example, the sequences of two DNA polymerases (e.g. Taq polymerase and another A family DNA polymerase) may be aligned, and the residues corresponding to the above-listed residues for Taq polymerase may be identified. In some embodiments, software may be used to perform the alignment and to identify residues predicted to have secondary structures vs. residues that are likely to be flexible loops. For sequences that do not completely align, residues ranges may be adjusted accordingly. For example, residues may be adjusted to account for extra residues, missing residues, etc. in one polymerase compared to the other. As one example, sequence alignment may be performed to determine that residues 782-786 of Taq polymerase correspond to residues 784-788 of Tth polymerase.

[0081] In some embodiments, flexible loops are considered the same loop topologically, although they may have different lengths and residue numbers. When protein sequences are aligned, the two flexible loops may not exemplify high level of alignment, but the regions surrounding the flexible loop are well aligned, thus confirming that the two flexible loops (e.g. the flexible loop in Taq polymerase and the flexible loop in another A family DNA polymerase) do indeed correspond to each other. In such embodiments, flexible loops identified as corresponding to any of the above-described flexible loops in Taq polymerase may be used as intein insertion sites in other A family DNA polymerases. In some embodiments, the target DNA polymerase is Taq polymerase or a chimera comprising at least a thumb domain from Taq polymerase, and the intein is inserted within a flexible loop in the thumb domain of the target DNA polymerase. In some embodiments, the intein is inserted in an H1H2 loop of the thumb domain of the target DNA polymerase. The H1H2 loop of Taq polymerase is 18 nucleic acids long. In some embodiments, the H1H2 loop of the TaqAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT polymerase comprises the sequence ELGLPAIGKTEKTGKRSTS (SEQ ID NO: 234). The intein can be inserted in any suitable position in the H1H2 loop, and mutations can be generated such that the intein is flanked by GG at one terminus and TG at the other terminus, thereby creating the CCTG insertion point. In some embodiments, intein is inserted within a flexible loop in the thumb domain, between amino acid positions 505 and 506 relative to SEQ ID NO: 1.

[0082] Any suitable intein may be used in the fusion proteins described herein. The intein may be a large intein, a mini-intein, or a split intein. Large inteins consist of an intein domain and an endonuclease domain. The endonuclease domain is inserted within the intein domain, separating the intein domain into two parts. Mini inteins contain only the intein domain (e.g. no endonuclease domain). Split inteins are inteins that are split into two fragments, and are able to conduct splicing only when the two fragments are properly folded together.

[0083] In some embodiments, the splicing activity of the intein is regulated by one or more factors. These external factors include physical factors such as light and temperature, and chemical factors such as pH, salt, ligand binding, etc. Activation of protein splicing results in release of the target DNA polymerase from the fusion protein. The released target DNA polymerase possesses increased activity (e.g. increased DNA polymerase activity and / or increased exonuclease activity) compared to the activity of the target DNA polymerase when present in the fusion protein.

[0084] In some embodiments, the one or more factors are selected from temperature, pH, and divalent ions. For example, the factor may be temperature. In such embodiments, the intein selected is referred to as a “temperature-sensitive” intein. For example, the splicing activity of a temperature-sensitive intein may be activated by temperatures of 30℃ or greater. As another example, the splicing activity of a temperature-sensitive intein may be activated by temperatures of 40℃ or greater. As another example, the splicing activity of a temperature-sensitive intein may be activated by temperatures of 50℃ or greater. For example, intein splicing may be activated by temperatures of at least 30℃, at least 35℃, at least 40℃, at least 45℃, at least 50℃, at least 55℃, at least 60℃, at least 65℃, greater than 70℃, or 70℃ to 80℃ .

[0085] Suitable temperature-sensitive inteins that may be used in the disclosed fusion proteins include, for example, PI-PfuI intein (Pyrococcus furiosus, UniProt ID: E7FHX6 (residue C302-N755)), PI-PfuII intein (Pyrococcus furiosus, UniProt ID: E7FHX6 (residue C915-Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT N1296)), Tth-HB27 DnaE-1 intein (Thermus thermophiles, Uniprot ID: Q72GP2 (residue C768- N1190)), Tmar Pol intein (Thermococcus marinus, UniProt ID: C7AIP4 (residue S492-N1028)), Tfu Pol-1 intein (Thermococcus fumicolans, UniProt ID: P74918 (residue C407-N777)), Tfu Pol- 2 intein (Thermococcus fumicolans, UniProt ID: P74918 (residue S901-N1289)), Psp-GBD Pol intein (Pyrococcus sp. (strain GB-D), UniProt ID: Q51334 (residue S493-N1029)), Mja TFIIB intein (Methanocaldococcus jannaschii, Uniprot ID: Q58192 (residue S100-N434)), Mvu TFIIB intein (Methanocaldococcus vulcanius, GenBank: ACX71902.1 (residue S93-N427)) and Sce VMA intein (alternative name: PI-SceI intein, Saccharomyces cerevisiae, UniProt ID: P17255 (residue C284-N737), PDB ID: 1DFA). Each of the above are large inteins. Each of the above may be used to create a corresponding mini intein by removing the endonuclease domain. Mini inteins derived from any of the above listed large inteins may be used in the fusion proteins described herein.

[0086] Additional suitable temperature-sensitive inteins include, for example, Pab PolII intein (Pyrococcus abyssi, UniProt ID: Q9V2F4 (residue C955-Q1139)) and Pho PolII intein (Pyrococcus horikoshii, GenBank ID: BAA29190.1 (residue C955-Q1120)). These are mini inteins. Other homologous inteins are potentially temperature sensitive, such as Tsi PolII intein (Thermococcus sibiricus, UniProt ID: C6A4U4 (residue C949-Q1114)), Tga PolII intein (Thermococcus gammatolerans, UniProt ID: C5A316 (residue C962-Q1125)), Tko PolII intein (Thermococcus kodakarensis, UniProt ID: Q5JET0 (residue C964-Q1437)), and Tba PolII intein (Thermococcus barophilus, UniProt ID: F0LKL3 (residue C952-N1426)).

[0087] Additional suitable temperature-sensitive inteins include, for example, Pho CDC21-1 intein (Pyrococcus horikoshii, GenBank ID: BAA29695.1 (residue C335-N502)), Pab CDC21-1 intein (Pyrococcus abyssi, GenBank ID CAB50345.1 (residue C335-N498)), and Tko CDC21-1 intein (Thermococcus kodakaraensis, GenBank: CAJ57164.1 (residue C1-N140)), Pho RadA intein (Pyrococcus horikoshii, UniProt ID: O58001 (residue C153-N324)), Tsi RadA intein (Thermococcus sibiricus, UniProt ID: C6A058 (residue C154-N321)) and Tvo VMA intein (Thermoplasma volcanium GSS1, UniProt ID: Q97CQ0 (residue C236-N421), PDB ID: 4O1S). These are mini inteins.

[0088] In some embodiments, a temperature-sensitive intein is a split intein. Suitable split inteins include Neq Pol intein (Nanoarchaeum equitans, GenBank: AAR38923.1 (S579-N676)Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT and GenBank: AAR39369.1 (residue M1-N30)) and Ssp DnaE intein (Synechocystis sp. strain PCC6803, UniProt ID: P74750 (residue C775-K897 and M898-N933), PDB ID: 1ZD7).

[0089] Other suitable inteins which may be temperature-sensitive include Mja KlbA intein (Methanocaldococcus jannaschii, Uniprot ID: Q58191 (residue A405-N572)), Pho CDC21-2 intein (Pyrococcus horikoshii, GenBank ID: BAA29695.1 (residue C530-N789)), Hsp CDC21 intein (Halobacterium sp. NRC‐1, GenBank ID: AAG20316.1 (residue C283-N464)), Hsp PolII intein (Halobacterium sp. NRC‐1, UniProt ID: Q9HMX8 (residue C926-Q1120)) and Mxe GyrA intein (Mycobacterium xenopi, UniProt ID: P72065 (residue C66-N263), PDB ID: 1AM2).

[0090] Sce VMA intein (alternative name: PI-SceI intein, Saccharomyces cerevisiae, UniProt ID: P17255 (residue C284-N737), PDB ID: 1DFA) has been engineered to be active in the desired temperature range (Zeidler et al., 2004) and may also be used in the fusion proteins described herein.

[0091] In some embodiments, the factor is divalent ions (e.g. divalent metal ions). For example, the presence of one or more divalent ions may suppress intein activity. Addition of a suitable agent to remove or otherwise negate the divalent ions may thus disinhibit the intein, allowing for splicing to occur. For example, a chelating agent may be added to bind the metal ion, thus activating the splicing ability of the intein. In some embodiments, the intein is sensitive to the divalent metal ion Zn2+. In some embodiments, the intein is sensitive to an alternative or additional divalent metal ion (e.g. another metal ion in addition to Zn2+).

[0092] Suitable Zn2+sensitive inteins include, for example, the large intein PI-PfuI intein (Pyrococcus furiosus, UniProt ID: E7FHX6 (residue C302-N755), PDB ID: 1DQ3), the large intein Mtu RecA intein (Mycobacterium Tuberculosis, GenBank: AMC51766.1 (residue C252- N691)), the mini intein Msm DnaB-1 intein (Mycolicibacterium smegmatis, GenBank: CKI67314.1 (residue A238-N376)), the split intein Ssp DnaE intein (Synechocystis sp. strain PCC6803, UniProt ID: P74750 (residue C775-K897 and M898-N933)), and the split intein Neq Pol intein (Nanoarchaeum equitans, GenBank: AAR38923.1 (S579-N676) and GenBank: AAR39369.1 (residue M1-N30)).

[0093] In some embodiments, the intein is selected from PI-PfuI intein (UniProt ID: E7FHX6 (residue C302-N755),PDB ID: 1DQ3), PI-PfuII intein (UniProt ID: E7FHX6 (residue C915-N1296)), Tth-HB27 DnaE-1 intein (Uniprot ID: Q72GP2 (residue C768-N1190)), Neq PolAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT intein (GenBank: AAR38923.1 (S579-N676) and GenBank: AAR39369.1 (residue M1-N30), PDB ID: 5OXZ), Tmar Pol intein (UniProt ID: C7AIP4 (residue S492-N1028)), Tfu Pol-1 intein (UniProt ID: P74918 (residue C407-N777)), Tfu Pol-2 intein (UniProt ID: P74918 (residue S901-N1289)), Pab PolII intein (UniProt ID: Q9V2F4 (residue C955-Q1139), PDB ID: 2LCJ), Pho PolII intein (GenBank ID: BAA29190.1 (residue C955-Q1120)), Tsi PolII intein (UniProt ID: C6A4U4 (residue C949-Q1114)), Tga PolII intein (UniProt ID: C5A316 (residue C962- Q1125)), Tko PolII intein (UniProt ID: Q5JET0 (residue C964-Q1437)), Tba PolII intein (UniProt ID: F0LKL3 (residue C952-N1426)), Psp-GBD Pol intein (UniProt ID: Q51334 (residue S493-N1029)), Pho CDC21-1 intein (GenBank ID: BAA29695.1 (residue C335-N502), PDB ID: 6RPQ), Pab CDC21-1 intein (GenBank ID CAB50345.1 (residue C335-N498), PDB ID: 6RPP), Tko CDC21-1 intein (GenBank: CAJ57164.1 (residue C1-N140)), Mja TFIIB intein (Uniprot ID: Q58192 (residue S100-N434), Mvu TFIIB intein (GenBank: ACX71902.1 (residue S93-N427)), Pho RadA intein (UniProt ID: O58001 (residue C153-N324), PDB ID: 4E2T), Tsi RadA intein (UniProt ID: C6A058 (residue C154-N321)), Mja KlbA intein (Uniprot ID: Q58191 (residue A405-N572), PDB ID:2JMZ), Pho CDC21-2 intein (GenBank ID: BAA29695.1 (residue C530-N789)), Hsp CDC21 intein (GenBank ID: AAG20316.1 (residue C283-N464)), Hsp PolII intein (UniProt ID: Q9HMX8 (residue C926-Q1120)), Mth RIR1 intein (GenBank: AAB85157.1 (residue C266-N399)), Mxe GyrA intein (UniProt ID: P72065 (residue C66- N263), PDB ID: 1AM2), Tvo VMA intein (UniProt ID: Q97CQ0 (residue C236-N421), PDB ID: 4O1S), Tac VMA intein (GenBank ID: BAB00608.1 (residue C236-N408)), Sce VMA intein (alternative name: PI-SceI intein UniProt ID: P17255 (residue C284-N737), PDB ID: 1DFA), Ssp DnaE intein (UniProt ID: P74750 (residue C775-K897 and M898-N933), PDB ID: 1ZD7), Npu DnaE intein (GenBank ID: ACC83218.1 (residue C775-N876) and GenBank ID: ACC83986.1 (residue M1-N36)), Ssp DnaB intein (UniProt ID: Q55418 (residue C381-N809)), Npu DnaB intein (GenBank ID: ACC81364.1 (residue C389-817N)), Msm DnaB-1 intein (GenBank: CKI67314.1 (residue A238-N376)), Mtu RecA intein (GenBank: AMC51766.1 (residue C252-N691)), gp41-1 intein (PDB ID: 6QAZ), Tko Pol-2 intein (GenBank: BAA06142.2 (residue S852-N1388), PDB ID: 2CW8), Cth BIL intein (GenBank: ABN53254.1 (residue C311-N445), PDB ID: 2LWY), Cne PRP8 intein (GenBank: AAX38543.1 (residue C1- N171), PDB ID: 6MX6).Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0094] In some embodiments, the intein is a pH sensitive intein. In some embodiments, the intein is sensitive to a plurality of factors. For example, the intein may be sensitive to temperature and pH. The intein may be sensitive to temperature and one or more divalent metal ions. The intein may be sensitive to temperature and pH and one or more divalent metal ions. The intein may be sensitive to pH and one or more divalent metal ions. The intein may be sensitive to additional factors not listed herein.

[0095] Any large intein may be made into a mini intein by removal of the endonuclease domain. The intein may comprise an amino acid sequence having 80% or more (e.g. at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with an intein described herein. For large inteins, the intein may comprise an amino acid sequence having 80% or more sequence identity with a mini intein derived from the large intein.

[0096] In some embodiments, the intein is PI-PfuI intein or a variant thereof. The sequence of wildtype PI-PfuI intein is: CIDGKAKIIFENEGEEHLTTMEEMYERYKHLGEFYDEEYNRWGIDVSNVPIYVKSFDPES KRVVKGKVNVIWKYELGKDVTKYEIITNKGTKILTSPWHPFFVLTPDFKIVEKRADELKE GDILIGGMPDGEDYKFIFDYWLAGFIAGDGCFDKYHSHVKGHEYIYDRLRIYDYRIETFE IINDYLEKTFGRKYSIQKDRNIYYIDIKARNITSHYLKLLEGIDNGIPPQILKEGKNAVLSFI AGLFDAEGHVSNKPGIELGMVNKRLIEDVTHYLNALGIKARIREKLRKDGIDYVLHVEE YSSLLRFYELIGKNLQNEEKREKLEKVLSNHKGGNFGLPLNFNAFKEWASEYGVEFKTN GSQTIAIINDERISLGQWHTRNRVSKAVLVKMLRKLYEATKDEEVKRMLHLIEGLEVVR HITTTNEPRTFYDLTVENYQNYLAGENGMIFVHN (SEQ ID NO: 2)

[0097] In some embodiments, the intein comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 2. For example, the intein may comprise an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with SEQ ID NO: 2.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0098] In some embodiments, the intein comprises a mini intein derived from the wild-type PI-PfuI intein (e.g. the large intein). For example, in some embodiments the intein comprises an amino acid sequence having at last 80% sequence identity with the PI-PfuI mini intein having the amino acid sequence: CIDGKAKIIFENEGEEHLTTMEEMYERYKHLGEFYDEEYNRWGIDVSNVPIYVKSFDPES KRVVKGKVNVIWKYELGKDVTKYEIITNKGTKILTSPWHPFFVLTPDFKIVEKRADELKE GDILIGGMPDGGLEVVRHITTTNEPRTFYDLTVENYQNYLAGENGMIFVHN (SEQ ID NO: 3).

[0099] In some embodiments, the intein comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with SEQ ID NO: 3.

[0100] The amino acid sequences of other suitable inteins are provided in WO2022046162A1, incorporated herein by reference for all purposes. In some embodiments, the intein comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with one of SEQ ID NO: 7 to SEQ ID NO: 233.

[0101] In some embodiments, the intein further comprises a linker. A linker attached to the intein is referred to herein as an “intein linker”. In some embodiments, the intein comprises an N-terminal linker and / or a C-terminal linker. Any suitable intein linker may be used. In some embodiments, the intein linker comprises 5 or less amino acids. In some embodiments, the intein linker comprises 5, 4, 3, 2, or 1 amino acid.

[0102] In some embodiments, the fusion protein further comprises a purification tag. Polyhistidine (His6) is a common purification tag and may be used. However, other suitable purification tags may be employed. In some embodiments, the purification tag further comprises a linker. A linker attached to the purification tag is referred to herein as a “tag linker”. In some embodiments, the purification tag comprises an N-terminal linker and / or a C-terminal linker.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT Any suitable tag linker may be used. In some embodiments, the tag linker comprises 5 or less amino acids. In some embodiments, the tag linker comprises 5, 4, 3, 2, or 1 amino acid. In some embodiments, the N-terminal tag linker comprises SG. In some embodiments, the C-terminal tag linker comprises GS.

[0103] In some embodiments, the purification tag is inserted within the intein. An appropriate insertion location should not affect the structure and function of the intein. Thus, flexible loops on the intein are preferred insertion positions for the purification tag. In some embodiments, the purification tag may be inserted within a flexible loop of an endonuclease domain in a large intein. In some embodiments, the purification tag may be inserted within a flexible loop within the sequence between the two fragments of a split intein or within the corresponding regions of a mini intein. In some embodiments, the purification tag is inserted within a flexible loop in a mini intein. In some embodiments, the purification is inserted within the mini intein to replace where the endonuclease domain would have been in the corresponding large intein. In some embodiments, the endonuclease domain of a large intein is replaced with a purification tag, thereby generating a mini intein containing the purification tag.

[0104] In some embodiments, the purification tag position on PI-PfuI intein is between residue Gly126 and Val418. This region is flexible and structurally conserved in some other inteins. Accordingly, this position may also be employed in other inteins besides the PI-PfuI intein.

[0105] In some embodiments, the intein comprises a PI-PfuI mini intein containing an N- terminal linker (e.g. SG), a terminal linker (e.g. GS), and a purification tag (e.g. HHHHHH (SEQ ID NO: 4)). Such a mini intein is set forth in the amino acid sequence of SEQ ID NO: 5. CIDGKAKIIFENEGEEHLTTMEEMYERYKHLGEFYDEEYNRWGIDVSNVPIYVKSFDPES KRVVKGKVNVIWKYELGKDVTKYEIITNKGTKILTSPWHPFFVLTPDFKIVEKRADELKE GDILIGGMPDGSGHHHHHHGSGLEVVRHITTTNEPRTFYDLTVENYQNYLAGENGMIFV HN (SEQ ID NO:5)

[0106] In some embodiments, the intein comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at leastAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with SEQ ID NO: 5.

[0107] The fusion proteins described herein may be incorporated into compositions. Such compositions find use in a variety of methods. Suitable methods include, for example, PCR, RT- PCR, reverse transcription, isothermal amplification, genotyping, cloning, mutation detection, sequencing, microarrays, forensics, paternity testing, diagnostic PCR, and gene synthesis. In some embodiments, the composition further comprises a nucleic acid template (e.g. a nucleic acid intended to be amplified). In some embodiments, the composition further comprises a reaction buffer. Suitable reaction buffers may comprise reagents necessary to perform the desired method. For example, reaction buffers may contain dNTPs, primers, probes, degradation inhibitors, surfactants, PCR additives (e.g. ammonium sulfate, DMSO, formamide, glycerol, and Triton X-100), buffers (e.g. sequencing buffer, PCR buffer, RT-PCR buffer), and the like. In some embodiments, provided herein is a composition comprising a fusion protein described herein containing the D119A mutation, and a fusion protein described herein containing the T509K mutation. In some embodiments, provided herein is a composition comprising a fusion protein described herein containing the D119A and the T509K mutation, and a fusion protein described herein containing the T509K mutation.

[0108] In some embodiments, the fusion proteins described herein may be incorporated into kits. For example, a kit may comprise a fusion protein and one or more additional components. The components of the kit may be packaged separately or together. The kit may additionally comprise instructions for using the kit. Instructions included in kits can be affixed to packaging material, can be included as a package insert, or can be viewed or downloaded from a particular website that is recited as part of the kit packaging or inserted materials. While the instructions are typically written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this disclosure. Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. As used herein, the term “instructions” can include the address of an internet site that provides the instructions. In some embodiments, the kit comprises a fusion protein as described herein and a suitable reaction buffer, depending on the intended use of the kit. For example, kits intended for use in RT-PCRAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT (e.g. one-step RT-PCR, two-step RT-PCR) may additionally comprise a suitable PCR reaction buffer. Kits intended for use in two-step RT-PCR may additionally comprise a reverse transcriptase. In some embodiments, provided herein is a kit for one-step RT-PCR comprising a fusion protein comprising a DNA polymerase possessing reverse transcriptase activity. Such a kit may be particularly useful for rapid and specific diagnostic tests, such as for SARS-CoV-2 or influenza.

[0109] In some aspects, provided herein are methods of using the fusion proteins described herein. In some embodiments, provided herein is a method of amplifying nucleic acid. In some embodiments, the method comprises providing a composition comprising a nucleic acid template and a fusion protein comprising a target DNA polymerase having one or more substitution mutations relative to wildtype and an intein inserted at a designated position in the target DNA polymerase. In some embodiments, the composition comprises a mixture of fusion proteins described herein. For example, in some embodiments the composition comprises a fusion protein comprising a target DNA polymerase comprising the D119A substitution mutation relative to SEQ ID NO: 1 and a fusion protein comprising a target DNA polymerase comprising the T509K substitution mutation relative to SEQ ID NO: 1. As another example, in some embodiments the composition comprises a fusion protein comprising a target DNA polymerase comprising the D119A substitution mutation and the T509K substitution mutation relative to SEQ ID NO: 1, and a fusion protein comprising a target DNA polymerase comprising the T509K substitution mutation relative to SEQ ID NO: 1. Insertion of the intein at the designated position inhibits activity of the target DNA polymerase. The method further comprises modifying one or more factors to induce release of the target DNA polymerase from the fusion protein. For example, the one or more factors may be temperature (e.g. increasing the temperature to activate the intein splicing), pH, or the presence of divalent ions (e.g. adding a chelator to bind the ions, thereby activating intein spicing activity). The released target DNA polymerase possesses increased activity compared to the target DNA polymerase containing the inserted intein. The method further comprises amplifying the nucleic acid template in the composition.

[0110] The fusion proteins provided herein enable amplification of RNA targets directly by PCR in the absence of additional enzymes. Moreover, the fusion proteins provided herein control the activity of both the DNA polymerase and the RTase activities with a single, hot-startAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT regulatory element, which is not achievable in other, multi-component amplification systems. Experiments conducted herein demonstrate that polymerases such as Taq polymerase may degrade RNA at the concentrations needed for amplification. In contrast, the fusion protein comprising the D119A mutation described herein amplifies target RNA, e.g. SARS-CoV-2 RNA, without problematic RNA degradation. The fusion protein comprising the T509K mutation was shown herein to enhance sensitivity of DNA amplification by improving substrate binding to the polymerase active site. The double mutant (e.g. the fusion protein comprising both the D119A and T509K mutation) can be used directly in qPCR schemes in which fluorescence product is detected by intercalating dyes, and in schemes that exploit changes in doubly labeled fluorescent probes that require no further modification (e.g. molecular beacons dual hybridization probes). Another, commonly used, detection method exploits the 5′→3′ exonuclease activity to generate a fluorescence signal by release of a fluorophore attached to the 5′ end of a probe, freeing it from quenching by a dye attached to the 3′ end of the probe. In such embodiments, a blended cocktail may be used comprising the double mutant in combination with the fusion protein comprising the T509K mutation, which allows sufficient exonuclease activity for probe hydrolysis while avoiding significant undesirable RNaseH activity.

[0111] In some embodiments, protein splicing activity of the intein is regulated by the one or more external factors. As described above, these external factors may include physical factors such as light and temperature, and chemical factors such as pH, salt, ligand binding, etc. Activation of protein splicing as a result of modifying the one or more factors results in release of the target DNA polymerase from the fusion protein. The released target DNA polymerase possesses increased activity (e.g. increased DNA polymerase activity and / or increased exonuclease activity) compared to the activity of the target DNA polymerase when present in the fusion protein. Accordingly, the methods described herein allow for the target DNA polymerase to only perform its enzymatic function when desired characteristics are achieved. For example, the methods described herein allow for the target DNA polymerase to only perform its enzymatic function when a set temperature and / or pH is achieved, thereby activating the intein and inducing the splicing reaction, thereby freeing the DNA polymerase from the inhibition of the intein. As another example, the methods described herein allow for the target DNA polymerase to perform its enzymatic function when a suitable agent (e.g. chelating agent) is added to the compositionAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT disinhibit the intein from a divalent metal ion, thereby activating the splicing reaction and inducing release of the DNA polymerase from the fusion protein. Such methods are therefore useful in allowing for amplification of a nucleic acid template only when desired, thus reducing non-specific amplification.

[0112] In some embodiments, the fusion proteins or compositions comprising the same find use in methods involving reverse transcription. Reverse transcription (RT) is the process of synthesizing DNA from an RNA template. It can be followed by a PCR reaction to amplify the synthesized DNA. Reverse transcription-polymerase chain reaction (RT-PCR) is the coupling of reverse transcription reaction and PCR. This technology is widely used for synthesizing the cDNA from mRNA, or detecting specific target sequence from any RNA source such as viral genome RNA. The reaction starts with the reverse transcription catalyzed by a polymerase containing reverse transcriptase activity, which synthesizes the DNA fragment complementary to the RNA template. Then in the regular PCR step, a PCR compatible polymerase amplifies the target DNA fragment using the DNA template synthesized from the reverse transcription step.

[0113] In general, RT-PCR is performed using one reverse transcriptase (RT family DNA polymerases) for RT and one thermally stable DNA polymerase for PCR. Currently, the widely used reverse transcriptases from viruses can synthesize long DNA products at a high rate. However, these enzymes are not thermally stable and could inhibit PCR reaction. Additionally, these reverse transcriptases require a low temperature for RT, which leads to nonspecific DNA synthesis catalyzed by the DNA polymerase. Accordingly, the fusion proteins described herein would be advantageous over those currently used in the art due to their thermal stability and conditional activation (e.g. temperature sensitivity of the intein). In some embodiments, the fusion protein and compositions described herein may be used for one-enzyme RT-PCR (e.g. one-step RT-PCR). For example, fusion proteins comprising a DNA polymerase with both reverse transcriptase and DNA polymerase activity may be employed for one-enzyme RT-PCR methods (e.g. without the need for an additional reverse transcriptase). In other embodiments, the fusion proteins and compositions described herein may be used for two-enzyme RT-PCR (e.g. two-step RT-PCR), by using a separate enzyme with reverse transcriptase activity and subsequently using a fusion protein comprising a DNA polymerase as described herein.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0114] An RNA extraction step is usually conducted before RT-PCR for virus detection. It denatures viral capsid to release viral RNA for detection and denatures RNases to protect RNA samples. It can be conducted using an RNA extraction kit and usually includes heat treatment to break the virus. This step could take 30 minutes or longer and part of the RNA sample could be lost during this process. The reason that this heat-treated RNA extraction is typically a separate step is that common reverse transcriptases are not thermally stable. Therefore, they cannot withstand the heat during RNA extraction. Hence, a separated step is required, which adds complexity to the virus detection process and increases the odds of error. The denatured RNases could also refold between these steps and new RNases contamination could be introduced into the reaction. In contrast, in some embodiments the fusion proteins provided herein may be subjected to heat treatment directly in the RT-PCR reaction. For example, for thermally stable DNA polymerases described herein that have reverse transcriptase activity, the heat-treated RNA extraction step can be conducted directly in the RT-PCR reaction (referred to as heat-treatment RT-PCR, or HT-RT-PCR), since the polymerases can retain activity even after being boiled. Fusion proteins provided herein that find use in HT-RT-PCR possess numerous advantages. For example, since there is no transfer between the steps, all viral RNA is used directly for RT-PCR and the loss of the RNA sample could be minimized. In addition, handling time can be greatly shortened by cutting additional steps, and the risk of contamination is greatly reduced.

[0115] In some embodiments, the fusion protein may be mixed with other unmodified or modified DNA polymerases, such as an unmodified or modified Taq polymerase or Pfu polymerase, for its use.

[0116] In some embodiments, the fusion proteins described herein may be used in methods involving PCR. Polymerase Chain Reaction (PCR) is one of the most common reactions used in life sciences, medical, and clinical laboratories. It is used for synthesizing specific DNA sequences based on a template sequence through thermal cycles. A standard PCR thermal cycle contains three steps: denaturation, annealing, and synthesis. The denaturation step uses high temperature to generate the single strand template. Then, the annealing step lowers the temperature so that the designed oligonucleotide binds to the target position on the template. This designed oligonucleotide acts as the primer for DNA synthesis by providing the 3’-OH group and assigning the synthesis initiation position. During the synthesis step, the properAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT temperature is maintained for the DNA polymerase to catalyze DNA synthesis. New copies of DNA are generated in each thermal cycle, which are used as templates in the later cycles. Thus, repeating the three steps establishes a chain reaction to amplify the original DNA template. In quantitative PCR (qPCR, or real-time PCR), fluorescence is introduced during synthesis, so that the DNA products can be quantitatively measured in real-time. Many other PCR based technologies have also been developed for specific applications, such as digital PCR, solid-phase PCR, etc.

[0117] Standard PCR and modified versions have various applications, such as amplifying specific sequences, fusing sequences, generating mutations into DNA products, generating DNA sequence libraries, amplifying the whole genome, DNA de novo synthesis, introducing unnatural or modified nucleotides into DNA products, etc. Because the target sequence is amplified exponentially, PCR and PCR based technologies have been used to detect specific sequences, such as viral sequences, or single-nucleotide polymorphism (SNP) for clinical diagnoses. These applications have been routinely used in life sciences, medical, and clinical laboratories. The fusion proteins described herein may be used in any of these or other methods involving PCR.

[0118] In some embodiments, the fusion proteins and compositions described herein may be used in methods involving isothermal amplification. DNA polymerase based isothermal amplification is another technology for DNA synthesis. Isothermal amplification reactions are conducted at a constant temperature, which use the strand displacement activity of DNA polymerases, specifically designed primers, and additional enzymes to generate single-strand regions on the template for primer binding and DNA synthesis. Several isothermal amplification technologies have been commercialized: helicase-dependent amplification (HDA), recombinase polymerase amplification (RPA), rolling circle amplification (RCA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), multiple displacement amplification (MDA, also used for whole genome amplification, WGA), ramification amplification (RAM), etc. DNA polymerase based isothermal amplification technologies have been widely used for nucleic acids amplification and detection. The fusion proteins described herein may be used in any of these methods.

[0119] In some embodiments, the fusion proteins and compositions described herein may be used in methods involving sequencing. DNA or RNA sequencing is the technique to determineAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT the sequence of nucleotides in DNA or RNA. DNA polymerase duplicates a template strand by probing the base information of the template strand and accordingly incorporating the correct nucleotides into the newly synthesized strand. Thus, DNA polymerase mediated synthesis can be used to sequentially extract nucleotide information of a template. So far, three generations of sequencing technologies have been developed. The first generation sequencing is Sanger sequencing, which is a PCR based sequencing technology. DNA polymerase randomly incorporates different fluorescence-labeled dideoxynucleotides that terminate DNA synthesis, producing fluorescence-labeled DNA products with all possible lengths. The fluorescence provides the base information of the nucleotide, and the length of the DNA product provides the position information of the nucleotide. The combination of both information results in the sequence of the template. The second generation sequencing, or next-generation sequencing (NGS, short-read NGS), is a high throughput sequencing technology. The sample is first broken down to small fragments, followed by PCR based clonal amplification of each fragment. Each fragment is then sequenced by different strategies and combined into the sequence of the template. The third generation sequencing (long-read NGS, single molecule sequencing) extends the read for each sequencing process and directly reads the sequence of the sample, while some third generation sequencing technologies use PCR to amplify the sample. Each of these sequencing technologies require DNA polymerases to amplify the sample by PCR (first, second, and some third generation), incorporate labeled nucleotides (first, some second, and some third generation), and generate reads by DNA synthesis (first, some second, and some third generation). The fusion proteins and compositions described herein may be used in any of these sequencing methods.

[0120] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope. EXAMPLE 1

[0121] DNA polymerases are essential for nucleic acid synthesis, cloning, sequencing and molecular diagnostics technologies. Conditional intein splicing is a powerful tool for controlling enzyme reactions. Herein a thermal switch was engineered into thermostable DNA polymerases from two structurally distinct polymerase families by inserting a thermally activated inteinAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT domain into a surface loop that is integral to the polymerase active site, thereby blocking DNA or RNA template access. The fusion proteins are inactive, but retain their structures, such that the intein excises during a heat pulse delivered at 70–80°C to generate spliced, active polymerases. This straightforward thermal activation step provides a highly effective, one-component ‘hot- start’ control of PCR reactions that enables accurate target amplification by minimizing unwanted by-products generated by off-target reactions. In one engineered enzyme, derived from Thermus aquaticus DNA polymerase, both DNA polymerase and reverse transcriptase activities are controlled by the intein, enabling single-reagent amplification of DNA and RNA under hot-start conditions. This engineered polymerase provides high-sensitivity detection for molecular diagnostics applications, amplifying 5–6 copies of the tested DNA and RNA targets with >95% certainty. The engineered polymerases described herein along with methods of generating the same are described in Nucleic Acids Res. 2023 Jun 23; 51(11): 5883–5894., the entire contents of which is incorporated herein by reference for all purposes.

[0122] MATERIALS AND METHODS

[0123] Molecular Modeling:

[0124] Models were constructed using the structures of the wild-type PI-PfuI intein (PDB 1DQ3), Taq DNA polymerase (PDB 1TAQ, 3KTQ), and Pfu DNA polymerase (PDB 4AIL). Fusion protein models were constructed manually using Coot. Figures were generated using UCSF ChimeraX.

[0125] Mutant protein gene constructs:

[0126] The Taq DNA polymerase DNA fragment was amplified from pAKTaq using primers TaqF and TaqR (Table 1) and digested with NdeI and SalI. The pET-Taq expression plasmid was constructed by inserting this fragment into pET21a vector between NdeI and XhoI sites. An intein PI-PFUI-T DNA fragment was constructed from synthetic oligonucleotides (Table 2). The pET-InTaq expression plasmid was constructed by inserting the FseI and BamHI digest of PI- PFUI-T pET-Taq between FseI and BamHI sites. The Pfu DNA polymerase fragment was amplified from an expression plasmid using primers PfuF and PfuR (Table 1) and digested with NdeI and XhoI. The pET-Pfu expression plasmid was constructed by inserting this fragment into pET21a vector between NdeI and XhoI sites. An intein PI-PFUI-P DNA fragment wasAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT constructed from synthetic oligonucleotides (Table 2) The pET-InPfu expression plasmid was constructed by inserting the HindIII and XhoI digest of PFUI-P into pET-Pfu between HindIII and XhoI sites. The InTaq-T509K mutant and InTaq-D119A-T509K mutant were constructed using PCR-mediated site-directed mutagenesis (QuickChange, Agilent) (Table 1). The DNA sequences of the fusion proteins are given in Table 3.

[0127] Table 1 shows exemplary primers and synthesized oligonucleotides used TaqF 5’- C - - Q QAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT CPI-PFUI- 5’- T GGCCGGCCACCCCTTCAACCTCAACTCCCGGGACCAGCTGGAAAG TAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT T A T T A G T A C C G G A A A AAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT G T

[0129] Table 3: InTaq ATGCTGCCGCTGTTTGAACCGAAAGGTCGTGTCCTCCTGGTGGACGGCCAC G C C C C G G C A C C G C C CAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT A A T G C T A C C C A C C G C C C C G G

[0130] Protein expression and purification:

[0131] Expression plasmids were transformed into BL21 star (DE3) Rosetta 2 (ThermoFisher). The protein expression was started from transformants by preparing a 10 ml seed culture grown in LB broth (supplemented with 100 μg / l ampicillin and 34 μg / ml chloramphenicol) overnight at 37°C. The seed was used to inoculate 1 l LB broth, followed by growth at 37°C to 0.5–0.6 OD600, induction by addition of isopropyl β-D-1-thiogalactopyranoside to 0.5 mM, and continued growth for 6 h. Cells were harvested by centrifugation, and resuspended in lysis buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl), followed by lysis using five successive passes through a microfluidizer (Microfluidics). A clarified lysate was preparedAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT by centrifugation (20500 rpm) for 30 min at 4°C. The supernatant was decanted and loaded onto a 5-ml HisTrap column (Cytiva), pre-equilibrated with NiA buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl, 10 mM imidazole). Following washing with 500 mL NiA buffer, fusion proteins were eluted with NiB buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl, 300 mM imidazole). The eluted protein was diluted 10-fold with dilution buffer (5 mM Tris–HCl pH 8.0), and loaded onto a 5 ml HiTrap SP-5 ml HiTrap Q column tandem column (Cytiva). After loading, the HiTrap SP column was removed and the HiTrap Q column was washed with 50 mL QA buffer (20 mM Tris–HCl pH 8.0, 50 mM NaCl). The target protein was eluted with a 0–500 mM NaCl gradient (20 mM Tris–HCl pH 8.0). Fractions with purified target protein were pooled and stored at −80°C. The protein concentration was determined by UV absorption at 280 nm (InTaq, ^280= 144160 M−1cm−1; InPfu, ^280= 160440 M−1cm−1).

[0132] Protein splicing assay:

[0133] The purified protein was diluted to 0.5 mg / ml in QA buffer and incubated under the conditions indicated in the figures. The reaction products were separated with 8% SDS-PAGE, and visualized by staining with Coomassie Blue. All gels were analyzed by ImageJ to measure band intensities. Charts and plots were generated by GraphPad Prism 9.

[0134] Protein thermostability:

[0135] Thermostabilities were measured by differential binding of the fluorescent SYPRO dye to the unfolded state using a Bio-Rad CFX96 thermocycler to determine the temperature- dependent fluorescence (30–100°C, 0.5°C increments; 10 s intervals for signal acquisition) of 25 μl reactions (50 mM Tri-HCl pH 8.0, 100 mM KCl, 10× SYPRO Orange (Sigma), 5 μg protein). The first derivative of the fluorescent signal was calculated in Bio-Rad CFX Maestro.

[0136] DNA binding measurement using fluorescence polarization:

[0137] Fluorescence polarization of FAM (Fluorescein amidite) labeled primer-template DNA was determined with a SpectraMax M5e plate reader (Molecular Devices): 485 nm excitation (9 nm bandwidth), 525 nm emission (15 nm bandwidth) measured through polarization filters. The primer-template DNA was prepared by annealing the FA-primer to 3′ FAM labeled FA-template, 50 μl reactions (10 mM Tris–HCl pH 8.0, 50 mM KCl) contained 2 nM DNA substrate and varying protein concentrations (from a 2-fold serial dilution series). The polarization signal (mP) was calculated in SoftMax Pro.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0138] DNA polymerase assay:

[0139] DNA polymerase activities were determined by elongation of a self-priming DNA hairpin template. The hairpin (100 μM in water) was formed by annealing: 95°C for 5 min, on ice for 30 min. Mature DNA polymerases were prepared by incubating 50 μl full-length InTaq or InPfu (0.5 mg / ml; QA buffer) at 80°C for 1 h in a temperature cycler. The reactions were transferred to a spin column (BioRad) followed by pull-down depletion of the excised, His-tag labeled intein by addition of 100 μl of resuspended Ni-NTA beads (∼50% v / v). The mature protein was collected as the flow through. 50 μl reactions were prepared by mixing buffer (Taq DNA polymerase reaction buffer:10 mM Tris–HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 0.05% (v / v) Tween-20, 0.05% (v / v) IGEPAL CA-630; Pfu DNA polymerase reaction buffer: 120 mM Tris–HCl pH 8.8, 10 mM KCl, 6 mM ammonium sulfate, 2.5 mM MgCl2, 0.1% Triton X-100, 0.001% BSA) with varying amounts of protein (see figure legends), 0.2 μM DNA substrate, 0.2 mM of each dNTP in a 50 μl volume, and 5 mM EGTA (to prevent inhibition by adventitious non-Mg2+metals). The reactions were incubated at various temperatures and times as indicated. Following extension, 20 μl reaction aliquots were mixed with 20 μl 2× denaturing loading buffer (95% deionized formamide, 0.025% (w / v) bromophenol blue, 0.025% (w / v) xylene cyanol FF, 5 mM EDTA). Following incubation at 95°C for 5 min, 10 μl aliquots were loaded onto 10% 8 M urea–PAGE. After electrophoresis, the gel was stained by ethidium bromide and imaged under ultraviolet light.

[0140] 3′→5′ Exonuclease assay:

[0141] The 3′→5′ exonuclease activities were determined using a double-stranded DNA hairpin oligonucleotide. The hairpin substrate and spliced proteins were prepared as described above. 20 μl reactions were prepared by mixing protein (0.01 mg / ml) with 0.5 μM DNA substrate in Pfu DNA polymerase reaction buffer. Following incubation at 50°C for 1 h, 20 μl 2× denaturation loading buffer was mixed with each reaction, and the products analyzed by urea- PAGE as described above.

[0142] Endpoint PCR:

[0143] 50 μl reactions (Taq DNA polymerase reaction buffer or Pfu DNA polymerase reaction buffer) were prepared by mixing 500 ng InTaq or InPfu, 100 ng DNA templates, primers (0.2 μM each), and the four dNTPs (0.2 mM). The reactants were amplified in aAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT thermocycler (Mastercycler, Eppendorf): first, incubation at 70°C for 5 min; followed by 30 thermal cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 10 sec to 6 min depending on the target DNA length (1 kb / min). Following amplification 5 μl reaction aliquots were mixed with loading dye (30% glycerol, 0.025% (w / v) bromophenol blue, 0.025% (w / v) xylene cyanol FF) and loaded onto 1% agarose-TBE gel containing ethidium bromide (0.5 μg / ml). After electrophoresis, the gel was imaged under ultraviolet light.

[0144] Real-time PCR:

[0145] Amplification reactions were set up as described above, adding 1× EvaGreen dye. For amplification of the 72-mer SARS-CoV-2 N gene DNA, CDC 2019-nCoV_N1 primers were added at 0.4 μM each. The reactions were analyzed by quantitative PCR (qPCR) in a CFX96 thermocycler (Bio-Rad): first, incubation at 70°C for 10 min and 94°C for 1 min; followed by 40 thermal cycles of 94°C for 10 s, 63°C for 30 s. The fluorescence signal was scanned after each elongation step (63°C). The Cq values were determined using LinRegPCR (Ver. 2020.2). Upon completion of this amplification program, product melting curves were determined as described by the manufacturer. To quantify RNA targets (RT-qPCR), reaction products were analyzed by release of 5′-FAM from a probe. 25 μl reactions were prepared by mixing 500 ng InTaq blend or InTaqB+, 0.4 μM primers, 0.2 μM labeled probe, and four dNTPs (0.2 mM each) in 80 mM Tris– HCl pH 7.6, 4 mM MgCl2, 1 mM (NH4)2SO4, 5 mM EGTA, 50 mM KCl, 5% (v / v) glycerol, 10% (v / v) DMSO, 0.05% (v / v) TWEEN-20, 0.05% (v / v) IGEPAL CA-630. The reactions were amplified by qPCR: 70°C for 30 min and 60°C for 30min; followed by 45 thermal cycles of 94°C for 1 s and 60°C for 30 s. The DNA standard was purchased from Integrated DNA Technologies (Catalog # 10006625). The RNA standards were provided by Duke Human Vaccine Institute.

[0146] RNaseH activity assay

[0147] First, degradation of SARS-CoV-2 genomic RNA was assayed in 10 μl reactions by mixing 1 μl SARS-CoV-2 genomic RNA (104copies / μl, gift from Duke Human Vaccine Institute), 500 ng InTaq or InTaqE−, 1 unit / μl murine RNase inhibitor (New England Biolabs), with or without 4 mM MgCl2, with or without 0.625 μM each of CDC 2019-nCoV_N1 primers in 80 mM Tris–HCl pH 7.6, 1 mM (NH4)2SO4, 5 mM EGTA and 50 mM KCl. The reactions were incubated at 60°C or 37°C for 30 min. Second, the Luna Universal One-Step RT-qPCR kitAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT (New England Biolabs) was used to determine the amount of genomic RNA by RT-qPCR in the CFX96 thermocycler: 55°C for 30 min; followed by 45 thermal cycles of 94°C for 1 s and 60°C for 30 s.

[0148] RESULTS AND DISCUSSION

[0149] Structure-based design of intein-controlled A and B family DNA polymerases

[0150] Thermostable members of the A and B polymerase families are used for implementing molecular diagnostics and other nucleic acid technologies. The thermostable polymerases derived from Thermus aquaticus (Taq polymerase) and Pyrococcus furiosus (Pfu) represent the A and B family, respectively. These enzymes encode four activities of interest in separate (sub)domains (Figure 1): DNA polymerase which is present in both enzymes (fingers, thumb and palm domains); reverse transcriptase (thumb), which is absent in Pfu, but present at low levels in Taq, enabling this enzyme to be used for detecting RNA targets; 3′→5′ exonuclease which is absent in Taq, and present in Pfu, improving the replication fidelity of this enzyme; 5′→3′ exonuclease which is absent in Pfu, but present within an independent domain in Taq.

[0151] Herein, the mini-intein protein-splicing domain obtained from P. furiosus was used to control the activity of Taq and Pfu. If inserted into a properly folded protein, this domain catalyzes a splicing reaction at elevated temperatures. Splicing points typically impose intein- specific sequence limitations in the extein. For this mini-intein, the last two residues in the N- terminal extein are preferred to be GG, and TG for the first two residues in the C-terminal extein. Anecdotal studies suggest that the extein should be somewhat flexible at the insertion point in order to accommodate structural intermediates that arise in the course of the excision and ligation reactions. Accordingly, there are four key design principles for identifying placement positions of the mini-intein in the two polymerase genes. First, both the native polymerase and intein folds and their thermostabilities should persist in the engineered fusion protein. Otherwise, neither intein splicing can take place nor polymerase activity can be recovered following a heat pulse. Second, the polymerase activity is absent in the unspliced fusion, and is recovered in the spliced, mature enzyme, which is achieved by intein controlled DNA or RNA substrate accessibility to the polymerase. Third, the requisite splice-point GGTG tetrapeptide either is present serendipitously, or is introduced without compromising polymerase activity; fourth, the insertionAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT loop is either naturally flexible, or is lengthened to introduce flexibility for intein splicing without compromising polymerase activity in the mature enzyme.

[0152] Surface loops in the thumb domain provide the most compelling locations for satisfying these four design criteria. This mobile domain plays a role in binding the DNA substrate and processive catalysis. Consequently, insertions within a thumb loop are likely to be inactive. Neither Taq nor Pfu thumb loops contain GGTG (SEQ ID NO: 6) tetrapeptides. The sequences of the catalytic palm (sub)domains are highly conserved, but the thumb (sub)domain loop sequences are diverse, indicating that thumb domains are likely to be tolerant of the point mutations needed to set up the GGTG (SEQ ID NO: 6) splice junction. The Taq H1H2 loop is long (18 residues) and flexible (Figure 1C). Two point mutations were introduced in this loop to complete the GGTG (SEQ ID NO: 6) sequence for installation of the mini-intein fusion within InTaq (Figure 1A and 1B). The UV surface loop in the Pfu thumb is short (10 residues; Figure 1F). Accordingly, this loop length was expanded by two glycine residues, and a threonine mutation was introduced, which together created the GGTG (SEQ ID NO: 6) splice point to install the intein within InPfu (Figure 1D and 1E). A proline was also mutated to further increase loop flexibility, replacing it with a lysine to enhance affinity for the negatively charged DNA substrate.

[0153] Both fusion constructs contained a hexa-histidine sequence within the intein to facilitate selective affinity purification of the full-length protein (Figure 1G). Three additional variants were constructed to enhance InTaq. To prevent digestion by the 5′→3′ exonuclease activity of DNA targets at low copy numbers and RNA-DNA hybrids, a mutation was introduced to remove this activity. Guided by the structure of the 5′→3′ exonuclease domain and mutagenesis studies of the active site in an exonuclease that is homologous to this domain, a D119A mutation was introduced in the InTaqE−variant (Figure 1H). To improve amplification of low-copy number targets, binding of DNA or RNA substrates was enhanced by increasing the positive charge of the H1H2 loop via introduction of the T509K mutations in the InTaqB+variant (Figure 1H). The InTaqB+E−variant contains both mutations.

[0154] Two versions of InTaq were also constructed for use as controls. The first cysteine of the intein domain, which is required for the splicing reaction, was mutated to serine to construct a full-length fusion that cannot splice, In−Taq. The N-terminal 5′→3′ exonuclease domain wasAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT deleted, so that only the remaining DNA polymerase domain binds DNA substrates in InKlenTaq (Figure 1I). Finally, wild-type Taq, WtTaq, was produced from an expression construct.

[0155] Splicing of the engineered DNA polymerases is controlled by temperature and binding of transition metals

[0156] Both full-length InTaq and InPfu were produced at high levels by conditional expression in a T7 promoter plasmid construct and growth of an Escherichia coli strain in shaker flasks at 37°C. The two unspliced proteins were affinity purified via the hexa-histidine tag within the intein domain (∼30 mg of purified protein from 1L of bacterial culture).

[0157] Mature, spliced proteins formed rapidly from InTaq and InPfu upon incubation at 80°C; above 80°C, the splicing rates decrease (Figure 2A and 2B) By contrast, the proteins did not splice within a 2-h period upon incubation at 20°C (Figure 2C). Splicing therefore is temperature dependent, as intended, with an optimum at 70–80°C (Figure 2C).

[0158] Even though the splicing reaction is strongly temperature-dependent, it is not completely abolished following prolonged incubation (days) at room temperature (or a few months at −20°C). Several inteins are inhibited by divalent cations. The effect of cations on the splicing of InTaq was tested, and it was found that it was strongly inhibited by Zn2+, but not Mg2+(Figure 2D). Furthermore, this inhibition was reversed by addition of 5 mM EGTA (Figure 2E). Unlike antibody- or aptamer-inhibited Taq, Zn2+-inhibited InTaq withstood a prolonged heat pulse (Figure 2F). Zn2+inhibition was therefore used to stabilize unspliced InTaq and InPfu for robust, long-term storage. Following splicing, the chelated Zn2+does not interfere with polymerase activities (FIG. 6) / .

[0159] Intein splicing encodes binary control of DNA polymerase activity

[0160] DNA polymerase activities were measured using a self-priming hairpin, and it was found that unspliced InTaq did not exhibit any activity at 21°C for 1 h, even in 100-fold excess protein, whereas the spliced mature protein was as active as wild-type Taq (WtTaq) measured under identical conditions (Figure 3A). The behavior of InPfu was similar. Intein splicing therefore establishes a binary on / off switch of DNA polymerase activity under assay conditions, as intended.

[0161] The InTaq protein is foldedAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0162] The In−Taq mutant (inactive intein) was used to measure thermal stability of the full- length protein. Thermal denaturation revealed that like WtTaq, the polymerase and 5′→3′ exonuclease domains (un)fold independently in the unspliced In−Taq (Figure 3B). The mid- point denaturation temperatures of the In−Taq and WtTaq polymerase domains are approximately the same. However, the In−Taq 5′→3′ exonuclease domain is more stable. An additional thermal denaturation transition of the intein domain, which is expected to have a mid- point denaturation temperature above 100°C, in the accordance with the lifestyle of the P. furiosus hyperthermophile from which it is derived, was not observed. These results are consistent with a fully folded unspliced In−Taq, as intended according to design criterion 1.

[0163] The inserted intein domain inhibits substrate binding

[0164] The DNA polymerase and 5′→3′ exonuclease domains of Taq both bind DNA substrates independently. To measure the effect of the intein insert on substrate binding of the InTaq DNA polymerase domain alone, the truncated variant InKlenTaq was used (Figure 1I). Fluorescence anisotropy revealed that a fluorophore-labeled template-primer substrate binds to the spliced mature InKlenTaq, but not the full-length protein (Figure 3C). The intein therefore blocks DNA binding at the polymerase site, as intended.

[0165] Fluorescence anisotropy could not be used to measure substrate binding to InPfu, because this construct aggregates at the concentrations required for the assay (data not shown). We therefore assessed DNA binding indirectly. The activity of the Pfu 3′→5′ exonuclease domain is dependent on DNA substrate binding at the polymerase site. To test whether the InPfu intein also blocks DNA substrate binding, this exonuclease activity was measured using a 3′ recessed end in a hairpin substrate (Figure 3D). Only the mature, spliced InPfu exhibited 3′→5′ exonuclease, consistent with the intein inhibiting DNA substrate binding in InPfu as well.

[0166] InTaq and InPfu are effective PCR reagents

[0167] Prior to heat activation, InTaq remains inactive at 30°C, as does the commercial Antibody-Taq hot-start reagent, whereas WtTaq or Aptamer-Taq both extend a self-priming substrate (Figure 4A). Following heat activation, mature InTaq and InPfu both are effective reagents in standard PCR reactions, amplifying substrates varying from 0.3 to 6.1 kb in length (Figure 4B).Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0168] Accurate detection of low-copy number targets is enabled by effective intein-mediated ‘hot-start’

[0169] To determine whether InTaq improves the accuracy of detecting low copy numbers of a DNA substrate, a 72-mer fragment of the SARS-CoV-2 N gene was amplified with two primers recommended by the Centers of Disease Control (CDC) as a detection standard. A quantitative PCR (qPCR) scheme was used in which the amount of amplified DNA was detected using the EvaGreen dye that becomes fluorescent upon binding to double-stranded DNA (Figure 4C). First, the minimum number of amplification cycles that were needed to detect the serially diluted DNA substrate, Cq, were determined. Second, thermal denaturation of the PCR products was used to assess the homogeneity of the amplification products: uniform products exhibit single thermal transitions (peak of the signal first derivative with respect to temperature), whereas heterogeneous products exhibit multiple transitions, each associated with a molecular species of distinct stability. InTaq reliably amplified a single product species down to ∼30 copies in the reaction, whereas under these conditions WtTaq typically resulted in amplification of multiple species. Furthermore, WtTaq amplified primer dimers in the absence of added substrate, but InTaq did not. The InTaq therefore accurately detected a low-copy number target; WtTaq did not. Finally, the performance of InTaq is comparable to the Antibody-Taq hot-start reagent (FIG. 7) are both are slightly more reliable than Aptamer-Taq.

[0170] Intein-mediated control of InTaq reverse transcriptase activity enables high- sensitivity viral RNA detection

[0171] The Taq DNA polymerase also exhibits reverse transcriptase activity (RTase), enabling this enzyme to amplify RNA targets directly by PCR in the absence of additional enzymes. The InTaq construct has the additional, unique advantage that it controls the activity of both the DNA polymerase and the RTase activities with a single, hot-start regulatory element, which is not achievable in other, multi-component amplification systems. To deploy the InTaq for RNA detection by RT-qPCR, several properties were optimized. Detection of the N gene in the SARS-CoV-2 RNA genome was used as a test bed. The SARS-CoV-2 RNA was degraded by the InTaq enzyme used at the concentrations required for amplification. Introduction of the D119A mutation (Figure 1H) InTaqE−alleviated this problem (Figure 5A). Using a DNA substrate, EvaGreen-based qPCR detection sensitivity was enhanced by 2.7 cycles viaAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT introduction of the T509K mutation (Figure 1H) to improve substrate binding in InTaqB+(Figure 5B).

[0172] The InTaqB+E−double mutant can be used directly in qPCR schemes in which fluorescence product is detected by intercalating dyes, and in schemes that exploit changes in doubly labeled fluorescent probes that require no further modification (e.g. molecular beacons dual hybridization probes). Another, commonly used, detection method exploits the 5′→3′ exonuclease activity to generate a fluorescence signal by release of a fluorophore attached to the 5′ end of a probe, freeing it from quenching by a dye attached to the 3′ end of the probe. In order to use InTaq in such ‘probe hydrolysis’ detection schemes, a ‘blended’ cocktail was developed in which InTaqB+E−was mixed with small amounts of InTaqB+such that no significant RNaseH activity was introduced while providing sufficient 5′→3′ exonuclease activity for probe hydrolysi (Figure 5C).

[0173] High-sensitivity detection of RNA targets by InTaq required an initial 20–30 min 70°C incubation period, presumably to generate a sufficiently large population of spliced enzyme to support reverse transcription of low-copy number targets. Under these conditions, the blended InTaqB+E− / InTaqB+mixture was able to detect a minimum of 5–6 RNA copies per reaction using the probe hydrolysis method (Figure 5D). This limit of detection (LoD) corresponds to the threshold currently set by the Food and Drug Administration (FDA) for emergency use authorization. Even at 1–2 RNA copies per reaction, the assay still demonstrated near 60% certainty (Figure 5D, inset). The InTaqE−mutation achieved high sensitivity (Figure 5D).

[0174] Using InTaqB+E−, blended with InTaqB+to enable detection by probe hydrolysis, Simian immunodeficiency virus (SIV) gag gene RNA was also detected with similar sensitivity (Figure 5E). The 5′→3′ exonuclease activity also digests DNA targets. Accordingly, low-copy number DNA target detection with probe hydrolysis also benefits from using the InTaqB+E− / InTaqB+blend, which was used to detect DNA targets at 5 copies with 95% certainty (FIG. 8). InTaqB+E−therefore is an effective reagent for detecting RNA targets at low copy numbers by exploiting its combined RTase and polymerase activities

[0175] CONCLUSIONSAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0176] The current generation of hot-start reagents depend on the addition of a separate reagent at concentrations that inhibit the DNA polymerase and whose structure is thermally denatured, such as antibodies or aptamers, or non-specific chemical modification that is only partially reversed by heat. By contrast, the engineered DNA polymerases presented in this study are simple, single-component hot-start reagents. These reagents provide a generalizable, accurate and sensitive solution for DNA and RNA detection, amplifying 5–6 copies of the tested DNA and RNA targets with > 95% certainty.

[0177] The design strategy for constructing the thermally controlled intein fusions is extensible to other polymerases in the A and B families, because the surface loop into which the intein domain is introduced is structurally conserved and diverse in sequence. The intein inhibits the DNA polymerase activity, because it prevents binding of the DNA or RNA template. Consequently, other nucleic-acid processing enzymes also can be controlled in this manner, if these proteins have functionally equivalent domains in which at least one surface loop participates in DNA or RNA binding, and that are distinct from conserved regions in which catalysis is encoded. Introducing an intein into such loops satisfies the design criteria of retaining enzyme and intein structure, while inhibiting the activity of the former, but not the latter.

[0178] The modular nature of the design enables integration of other inteins that are controlled at different temperatures or by other signals. In the engineered DNA polymerases provided herein, the thermal splicing reaction and concomitant polymerase activity also can be controlled by divalent metals, including Zn2+, which is useful for long-term storage. Although the thermal excision of the currently deployed intein is relatively slow, it is sufficient to provide hot-start control for accurate PCR and RT-PCR reactions.

[0179] The splicing activities of several natural inteins can be controlled by pH or ionic strength. Light-sensitive inteins have been engineered using non-natural amino acids whose side- chains are reversibly modified with photoreactive groups. The ability to regulate multiple nucleic-acid processing enzymes with distinctly controlled (‘orthogonal’) inteins enables the design of engineered enzyme systems that carry out multi-step diagnostic or synthetic steps with exquisite levels of control.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT

[0180] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0181] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT CLAIM(S):

1. A fusion protein comprising a target DNA polymerase and an intein inserted at a designated position in the target DNA polymerase, wherein insertion of the intein at the designated position inhibits activity of the target DNA polymerase, wherein the target DNA polymerase is an A family DNA polymerase or a chimera comprising at least one domain from an A family DNA polymerase, and wherein the target DNA polymerase comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 and having a substitution mutation at position 119 and / or position 509 relative to SEQ ID NO:

1.

2. The fusion protein of claim 1, wherein the target DNA polymerase comprises a D119A substitution mutation and / or a T509K substitution mutation relative to SEQ ID NO:

1.

3. The fusion protein of claim 1 or claim 2, wherein the target DNA polymerase is an A family DNA polymerase selected from Taq polymerase, Tth polymerase, Tfl polymerase, Tfi polymerase, Tbr polymerase, Tca polymerase, Tma polymerase, Tne polymerase, Bst polymerase, Bsm polymerase, Bsu polymerase, E. coli DNA polymerase I, Bacteriophage T7 DNA polymerase, and 3173 Pol, or wherein the target DNA polymerase comprises at least one domain from an A family DNA polymerase selected from Taq polymerase, Tth polymerase, Tfl polymerase, Tfi polymerase, Tbr polymerase, Tca polymerase, Tma polymerase, Tne polymerase, Bst polymerase, Bsm polymerase, Bsu polymerase, E. coli DNA polymerase I, Bacteriophage T7 DNA polymerase, and 3173 Pol.

4. The fusion protein of claim 3, wherein the target DNA polymerase is Taq polymerase or wherein the target DNA polymerase is a chimera comprising at least one domain from Taq polymerase.

5. The fusion protein of any one of any one of the preceding claims, wherein insertion of the intein at the designated position in the target DNA polymerase inhibits polymeraseAttny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT activity and / or exonuclease activity of the target DNA polymerase, and / or wherein the intein is inserted at a designated position in the target DNA polymerase such that binding of a substrate to an active site of the target DNA polymerase is inhibited.

6. The fusion protein of any one of the preceding claims, wherein the intein is inserted within a flexible loop within a thumb domain, a finger domain, a palm domain, or an exonuclease domain of the target DNA polymerase.

7. The fusion protein of any one of the preceding claims, wherein the intein is inserted between 10 to 50 Å from the active site of the target DNA polymerase.

8. The fusion protein of any one of the preceding claims, wherein the intein is flanked by an N-terminal extein and a C-terminal extein of the target DNA polymerase, wherein the last two amino acids in the N-terminal extein are GG or are mutated to be GG, and wherein the first two amino acids in the C-terminal extein are TG or mutated to be TG.

9. The fusion protein of any one of the preceding claims, wherein the target DNA polymerase is Taq polymerase or a chimera comprising at least a thumb domain from Taq polymerase, and wherein the intein is inserted within a flexible loop in the thumb domain of the target DNA polymerase.

10. The fusion protein of claim 9, wherein the intein is inserted in a H1H2 loop in the thumb domain of the Taq polymerase.

11. The fusion protein of claim 9 or claim 10, wherein the intein is inserted between amino acid positions 505 and 506 relative to SEQ ID NO:

1.

12. The fusion protein of any one of the preceding claims, wherein the target DNA polymerase possesses enzymatic activity at temperatures of greater than 50℃.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT 13. The fusion protein of any one of the preceding claims, wherein the target DNA polymerase is stable at temperatures of greater than 60℃.

14. The fusion protein of any one of the preceding claims, wherein the intein is a large intein, a mini-intein, or a split intein.

15. The fusion protein of any one of the preceding claims, wherein the intein is selected from PI-PfuI intein, PI-PfuII intein, Tth-HB27 DnaE-1 intein, Neq Pol intein, Tmar Pol intein, Tfu Pol-1 intein, Tfu Pol-2 intein, Pab PolII intein, Pho PolII intein, Tsi PolII intein, Tga PolII intein, Tko PolII intein, Tba PolII intein, Psp-GBD Pol intein, Pho CDC21-1 intein, Pab CDC21-1 intein, Tko CDC21-1 intein, Mja TFIIB intein, Mvu TFIIB intein, Pho RadA intein, Tsi RadA intein, Mja KlbA intein, Pho CDC21-2 intein, Hsp CDC21 intein, Hsp PolII intein, Mth RIR1 intein, Mxe GyrA intein, Tvo VMA intein, Tac VMA intein, Sce VMA intein, Ssp DnaE intein, Npu DnaE intein, Ssp DnaB intein, Npu DnaB intein, Msm DnaB-1 intein, Mtu RecA intein, gp41-1 intein, Tko Pol-2 intein, Cth BIL intein, Cne PRP8 intein, and variants thereof.

16. The fusion protein of any one of the preceding claims, wherein protein splicing activity of the intein is regulated by one or more factors, wherein activation of protein splicing results in release of the target DNA polymerase from the fusion protein, and wherein the released target DNA polymerase possesses increased activity compared to the activity of the target DNA polymerase when present in the fusion protein.

17. The fusion protein of claim 16, wherein the released target DNA polymerase possesses increased DNA polymerase activity and / or increased exonuclease activity compared to the target DNA polymerase when present in the fusion portion.

18. The fusion protein of claim 16 or claim 17, wherein the one or more factors are selected from temperature, pH, and divalent ions.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT 19. The fusion protein of claim 18, wherein protein splicing activity of the intein is activated by temperatures of 30℃ or greater.

20. The fusion protein of claim 18, wherein protein splicing activity of the intein is activated by temperatures of 40℃ or greater.

21. The fusion protein of claim 18, wherein protein splicing activity of the intein is activated by temperatures of 50℃ or greater.

22. The fusion protein of claim 18, wherein the factor is a divalent ion, wherein the presence of one or more divalent ions inhibits protein splicing activity of the intein.

23. The fusion protein of any one of the preceding claims, wherein the wild-type form of the intein is found in a thermophilic organism.

24. The fusion protein of any one of the preceding claims, wherein the intein is stable at temperatures of greater than 50℃.

25. The fusion protein of any one of the preceding claims, wherein the intein comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:

3.

26. The fusion protein of any one of the preceding claims, further comprising a purification tag, wherein the tag is inserted within the intein.

27. A composition comprising the fusion protein of any one of the preceding claims.

28. The composition of claim 27, comprising the fusion protein comprising a target DNA polymerase having a D119A substitution mutation and the fusion protein comprising a target DNA polymerase having a T509K substitution mutation relative to SEQ ID NO: 1.Attny Docket No. DUKE-43050.601 Client Ref. No. DU7163PCT 29. The composition of claim 27, comprising the fusion protein comprising a target DNA polymerase comprising the D119A substitution mutation and the T509K substitution mutation relative to SEQ ID NO: 1, and the fusion protein comprising a target DNA polymerase comprising the T509K substitution mutation relative to SEQ ID NO:

1.

30. The composition of any one of claims 27-29, further comprising a nucleic acid template and / or a reaction buffer.

31. Use of the composition of any one of claims 27-30 in a method of amplifying a nucleic acid template.

32. A method of amplifying nucleic acid, comprising: a. providing a sample comprising the fusion protein of any one of claims 1-26 and a nucleic acid template; b. modifying one or more factors in the sample to induce release of the target DNA polymerase from the fusion protein, wherein the released target DNA polymerase possesses increased activity compared to the target DNA polymerase containing the inserted intein; and c. amplifying the nucleic acid template in the composition, 33. The method of claim 32, wherein the modifying one or more factors comprises modifying the temperature of the sample and / or modifying the availability of divalent ions in the sample.

34. A kit comprising the fusion protein of any one of claims 1-26.

Citation Information

Patent Citations

  • Compositions and methods utilizing DNA polymerases

    US20080280291A1

  • Mutant polymerases and uses thereof

    US20210348142A1

  • Engineered polymerases and methods of using the same

    WO2022046162A1

Cited By

  • Engineering hot start Taq DNA polymerase variant and full premixing kit thereof

    CN122235110A